<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Heparin (unfractionated): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Heparin (unfractionated): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Heparin (unfractionated): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8518" href="/d/html/8518.html" rel="external">see "Heparin (unfractionated): Drug information"</a> and <a class="drug drug_patient" data-topicid="11753" href="/d/html/11753.html" rel="external">see "Heparin (unfractionated): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867107"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Heparin Leo</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1053161"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anticoagulant</span></li></ul></div>
<div class="block don drugH1Div" id="F53462465"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Manyconcentrations of heparin are available and range from 1 to 20,000 units/mL. Carefully examine each prefilled syringe, bag, or vial prior to use to ensure that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of IV devices and is not to be used for anticoagulant therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3fb46c65-111d-4fc3-a11d-a07df4fc63af">Central line flush, patency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central line flush, patency (intermittent doses):</b> Limited data available: Various recommendations exist for intermittent flushes of heparin used to maintain patency of single and double lumen central catheters; dose of heparin flush used should not approach therapeutic unit per kg dose; refer to institution-specific protocols. In neonates, the 10 units/mL concentration is used with frequency and volume of flushing determined by the type of catheter; capped polyvinyl chloride catheters and peripheral heparin locks require flushing more frequently (eg, every 6 to 8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater) or may be standardized according to specific NICU policy (eg, 0.5 to 1 mL/flush). Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cloherty.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cloherty.2017'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c1ea29a6-5109-46a1-815a-b58037a00b21">Central venous access device, patency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central venous access device (CVAD), patency:</b> Continuous IV infusion: 0.5 unit/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98069eb3-2214-4038-800a-65b82f8bd5ac">Congenital heart defect palliated with systemic to pulmonary artery shunts or with high-risk central venous lines, thromboprophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital heart defect palliated with systemic to pulmonary artery shunts (eg, Sano shunt, Blalock-Taussig shunt, central shunt) or with high-risk central venous lines (eg, previous thrombosis or hypercoagulable state), thromboprophylaxis:</b> Low dose: Continuous IV infusion: 10 to 15 units/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24226806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24226806'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16fb237d-81b2-4bd8-b2a2-d8f81eee571c">Extracorporeal membrane oxygenation, anticoagulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extracorporeal membrane oxygenation (ECMO) (venoarterial [VA]/cardiac), anticoagulation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> While used to prevent thrombosis, full anticoagulation dosing is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 100 units/kg prior to ECMO cannulation followed by continuous heparin infusion to maintain the activated clotting time (ACT) between 180 and 220 seconds; ACT should be checked hourly while patient is on ECMO; additional monitoring targets for heparin therapy are prolongation of the PTT to 1.5 to 2.5 times the control value or an anti-Xa level of 0.3 to 0.7 units/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24226806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24226806'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e621439a-9c5e-45cd-9a37-35de17d3452a">Parenteral nutrition additive, venous access patency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition (PN) additive, venous access patency:</b> 0.5 to 1 unit/mL (final heparin concentration in the PN solution), both central and peripheral PN solutions. The final concentration of heparin used for PN solutions may need to be decreased in small neonates receiving larger PN volumes in order to avoid approaching therapeutic amounts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkin.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkin.2015'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d469d7fd-0aae-4111-94ed-d3e9bc88e0ea">Peripheral arterial catheters in situ, thromboprophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral arterial catheters in situ, thromboprophylaxis:</b> Intra-arterial (via arterial catheter): Continuous infusion of heparin at a final concentration of 5 units/mL at 1 mL/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-3545674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-3545674'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8cb2292-ae3b-4081-8c17-df4c26f4d30c">Umbilical artery catheter, patency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Umbilical artery catheter (UAC), patency:</b> Intra-arterial (via UAC): Continuous infusion of heparin at a final concentration of 0.25 to 1 unit/mL; total heparin dose of 25 to 200 units/kg/day to maintain patency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dffcde2f-596f-4a63-a197-70c99b4c563b">Thrombosis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombosis, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic heparinization:</i> IV: Initial loading dose: 75 units/kg over 10 minutes; then initial continuous maintenance infusion at 28 units/kg/hour; adjust dose to maintain an anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or a protamine titration range of 0.2 to 0.4 units/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Because of variation among hospitals with reagents (lot numbers) and corresponding control of aPTT values, individual institutions should establish unique, institution-specific nomograms based on current reagent. Due to extensive variability within reagents and anti-Xa levels with corresponding aPTTs, a specific nomogram has not been provided; refer to guidelines for a specific nomogram (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic to pulmonary artery shunt thrombosis (eg, Sano shunt, Blalock-Taussig shunt, central shunt); treatment in patients with congenital heart disease (CHD):</i> Bolus: 50 to 100 units/kg, ongoing continuous infusion should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24226806','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24226806','lexi-content-ref-33081526'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F178776"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Many concentrations of heparin are available and range from 1 to 20,000 units/mL. Carefully examine each prefilled syringe, bag, or vial prior to use to ensure that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of IV devices and is not to be used for anticoagulant therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3fb46c65-111d-4fc3-a11d-a07df4fc63af">Central line flush, patency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central line flush, patency (intermittent doses):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-27222450','lexi-content-ref-24794887','lexi-content-ref-17040550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-27222450','lexi-content-ref-24794887','lexi-content-ref-17040550'])">Ref</a></span>): Infants, Children, and Adolescents: When using intermittent flushes of heparin to maintain patency of single and double lumen central catheters, various recommendations exist; refer to institution-specific protocols. Capped polyvinyl chloride catheters and peripheral heparin locks require flushing more frequently (eg, every 6 to 8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater). Dose of heparin flush used should not approach therapeutic unit per kg dose. Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98069eb3-2214-4038-800a-65b82f8bd5ac">Congenital heart defect palliated with systemic to pulmonary artery shunts or with high-risk central venous lines, thromboprophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital heart defect palliated with systemic to pulmonary artery shunts (eg, Sano shunt, Blalock-Taussig shunt, central shunt) or with high-risk central venous lines (eg, previous thrombosis or hypercoagulable states), thromboprophylaxis:</b> Infants, Children, and Adolescents: Low Dose: Continuous IV infusion: 10 to 15 units/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24226806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24226806'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16fb237d-81b2-4bd8-b2a2-d8f81eee571c">Extracorporeal membrane oxygenation, anticoagulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extracorporeal membrane oxygenation (ECMO) (venoarterial [VA]/cardiac), anticoagulation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> While used to prevent thrombosis, full anticoagulation dosing is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 100 units/kg prior to ECMO cannulation followed by continuous IV heparin infusion to maintain the activated clotting time (ACT) between 180 and 220 seconds; ACT should be checked hourly while patient is on ECMO; additional monitoring targets for heparin therapy are prolongation of the PTT to 1.5 to 2.5 times the control value or an anti-Xa level of 0.3 to 0.7 units/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24226806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24226806'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e621439a-9c5e-45cd-9a37-35de17d3452a">Parenteral nutrition additive, venous access patency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition (PN) additive, venous access patency:</b> Infants, Children, and Adolescents: 1 unit/mL (final heparin concentration in PN), both central and peripheral. The final concentration of heparin used for PN solutions may need to be decreased to 0.5 units/mL in small infants receiving larger PN volumes in order to avoid approaching therapeutic amounts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkin.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkin.2015'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d469d7fd-0aae-4111-94ed-d3e9bc88e0ea">Peripheral arterial catheters in situ, thromboprophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral arterial catheters in situ, thromboprophylaxis:</b> Infants, Children, and Adolescents: Intra-arterial (via arterial catheter): Continuous infusion of heparin at a final concentration of 5 units/mL at 1 mL/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-3545674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-3545674'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dffcde2f-596f-4a63-a197-70c99b4c563b">Thrombosis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombosis, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic heparinization: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: Initial loading dose: 75 units/kg over 10 minutes; then initial continuous maintenance infusion at 28 units/kg/hour; adjust dose to maintain an anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or a protamine titration range of 0.2 to 0.4 units/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-28552474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-28552474'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: Initial loading dose: 75 units/kg over 10 minutes, then initial continuous maintenance infusion at 20 units/kg/hour; adjust dose to maintain an anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or a protamine titration range of 0.2 to 0.4 units/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-28552474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-28552474'])">Ref</a></span>). <b>Note: </b>A lower initial continuous maintenance infusion dose of 18 units/kg/hour in older patients has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28552474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28552474'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Because of variation among hospitals with reagents (lot numbers) and corresponding control of aPTT values, individual institutions should establish unique, institution-specific nomograms based on current reagent. Due to extensive variability within reagents and anti-Xa levels with corresponding aPTTs, a specific nomogram has not been provided; refer to guidelines for a specific nomogram (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic to pulmonary artery shunt thrombosis (eg, Sano shunt, Blalock-Taussig shunt, central shunt); treatment in patients with congenital heart disease (CHD):</i> Infants, Children, and Adolescents: IV: Bolus: 50 to 100 units/kg, ongoing continuous infusion should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24226806','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24226806','lexi-content-ref-33081526'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112877"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity</p></div>
<div class="block dohp drugH1Div" id="F51112878"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity</p></div>
<div class="block doa drugH1Div" id="F178757"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8518" href="/d/html/8518.html" rel="external">see "Heparin (unfractionated): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Many concentrations of heparin are available ranging from 1 to 20,000 units/mL. Carefully examine each prefilled syringe or vial to ensure the correct concentration is selected.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> For weight-based IV heparin, an institution-specific dosing nomogram may help to achieve therapeutic anticoagulation more rapidly (see example based on aPTT under "Venous thromboembolism treatment"). If unusually large doses of heparin are required to achieve therapeutic targets, consider possible heparin resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.2022.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.2022.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e5dc550-d5c6-4105-9041-a9d5cb9b1fab">Antibiotic lock technique, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antibiotic lock technique, adjunctive therapy (catheter-salvage strategy) (off-label use):</b>
<b>Note:</b> Antibiotic lock therapy is used in addition to systemic antibiotics for certain catheter-related infections when the catheter cannot be removed. Heparin is incompatible with ethanol and should not be used with ethanol lock therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27441664','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27441664','lexi-content-ref-19489710'])">Ref</a></span>). Heparin is also incompatible with certain antibiotics; confirm compatibility prior to use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24296841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24296841'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intracatheter:</b> 100 to 5,000 units/mL in combination with an appropriate antibiotic. Heparin concentration depends on compatibility with the selected antibiotic, antibiotic concentration, and catheter type, which may vary by institution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24296841','lexi-content-ref-19193593','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24296841','lexi-content-ref-19193593','lexi-content-ref-19489710'])">Ref</a></span>). For patients with end-stage renal disease requiring hemodialysis, maximum final heparin concentration should not exceed 1,000 units/mL due to increased risk of bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17635828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17635828'])">Ref</a></span>). Instill into each lumen of the catheter access port using a sufficient volume to fill the catheter (eg, 2 to 5 mL) with a maximum dwell time of ≤72 hours, depending on frequency of catheter use. Withdraw lock solution prior to catheter use; replace with fresh lock solution after catheter use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19193593','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19193593','lexi-content-ref-19489710'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3365c250-d192-4d1f-bac1-c7ede7b463d1">Atrial fibrillation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation (to prevent stroke and systemic embolism): </b>
<b>Note:</b> When admitted for short-term hospitalization (eg, admission for a procedure or surgery), ambulatory patients taking an oral anticoagulant and <i>not</i> at high risk of immediate thromboembolism typically do not require bridging anticoagulation. Patients at high risk of thromboembolism (eg, recent cardioversion, high CHA<sub>2</sub>DS<sub>2</sub>-VASc score, prior cardioembolic stroke, current intracardiac thrombus) may be considered for bridging with a parenteral anticoagulant (see <b>
<i>Transitioning between anticoagulants</i></b> below) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315271'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial bolus of 60 to 80 units/kg (maximum: 5,000 units), followed by a continuous infusion of 12 to 18 units/<b>kg</b>/hour (maximum: 1,000 units/hour). Institutional dosing protocols may vary; adjust infusion rate to maintain anticoagulation target (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315264','lexi-content-ref-22315271','lexi-content-ref-Dager.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315264','lexi-content-ref-22315271','lexi-content-ref-Dager.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9847bd6f-8b5b-4188-820d-1d7ac6e351ba">Frostbite</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Frostbite (adjunctive agent) (off-label use):</b>
<b>Note:</b> Patients should be transferred to a facility that is familiar with managing patients with frostbite. Anticoagulation may be used in conjunction with thrombolytic therapy, either concurrently or following administration of the thrombolytic, but not as monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31899512','lexi-content-ref-27606554','lexi-content-ref-31326282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31899512','lexi-content-ref-27606554','lexi-content-ref-31326282'])">Ref</a></span>). Optimal regimens, administration routes, and doses, including the use of therapeutic or low-dose anticoagulation after thrombolytic therapy, have not been identified; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Example regimens include:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>When thrombolytic is administered IV: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 500 to 1,000 units/hour as a fixed dose or targeted to an aPTT 2× control for up to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31326282','lexi-content-ref-Zafren.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31326282','lexi-content-ref-Zafren.1'])">Ref</a></span>); some centers extend the duration to up to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21965579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21965579'])">Ref</a></span>) <b>or</b> transition to therapeutic low-molecular-weight heparin (LMWH) (eg, enoxaparin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27606554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27606554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>When thrombolytic is administered intra-arterial: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Intra-arterial:</b> 500 units/hour administered through the intra-arterial catheter; targeted to a goal aPTT 50 to 70 seconds; after discontinuation of thrombolytic therapy, continue anticoagulation for 72 to 96 hours <b>or</b> transition to therapeutic LMWH (eg, enoxaparin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17576891','lexi-content-ref-25687362','lexi-content-ref-32341921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17576891','lexi-content-ref-25687362','lexi-content-ref-32341921'])">Ref</a></span>). Instead of intra-arterial heparin, some suggest the use of IV heparin after intra-arterial thrombolytic (see IV dosing above) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25950290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25950290'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b870572b-8e81-4f96-9f72-5c886f42e20f">Hemodialysis, anticoagulation of circuit</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, anticoagulation of circuit:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Standard dosing has not been established for intermittent hemodialysis or CRRT. Recommendations provided below are example regimens. Refer to institutional protocols. May need to individualize dose based on patient-specific needs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Intermittent hemodialysis:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Standard risk for bleeding:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Initial: Bolus 1,000 units or 2,000 units at the beginning of hemodialysis, followed by a continuous infusion of 500 units/hour; stop the infusion 60 minutes before the end of hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If clotting occurs during first half of hemodialysis session</i>: Increase IV bolus by 500 units before each subsequent session (eg, administer 1,500 units or 2,500 units, depending on the previously attempted dose, at the beginning of hemodialysis) until clotting no longer occurs or up to a maximum of 4,000 units; administer continuous infusion as described above (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If clotting occurs during second half of hemodialysis session</i>: Administer the same IV bolus dose, but increase continuous infusion by 100 units/hour for each subsequent session (eg, administer 600 units/hour) until clotting no longer occurs or up to a maximum of 1,000 units/hour; stop the infusion 30 minutes before the end of hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>High risk for bleeding:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> There is no standard practice to prevent clotting of the hemodialysis circuit among patients who are at high risk for bleeding. Dialysis <i>without</i> heparin is preferred, but may consider heparin anticoagulation in patients who continue to have recurrent filter thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kovalik.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kovalik.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Initial: Bolus 1,000 units at the beginning of hemodialysis; do not administer a continuous infusion during the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If clotting occurs during hemodialysis:</i> IV: Bolus 1,000 units at the beginning of the subsequent hemodialysis session, followed by a continuous infusion of 500 units/hour; stop the infusion 60 minutes before the end of hemodialysis; if clotting continues, increase continuous infusion by 100 units/hour at each subsequent session (eg, administer 600 units/hour) until clotting no longer occurs or up to a maximum of 1,000 units/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kovalik.2020','lexi-content-ref-22560830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>CRRT</i>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For patients who require anticoagulation due to repeated clotting of hemofilter and when regional citrate anticoagulation is not feasible or unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: Bolus 500 to 1,000 units, followed by a continuous infusion of 500 units/hour; titrate to maintain an aPTT ~1.5 times the control or ~45 seconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.2020','lexi-content-ref-32164041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.2020','lexi-content-ref-32164041'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="99d890b6-bd0a-46ae-8a3d-9dd9c5d020b5">Ischemic heart disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ischemic heart disease: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Acute coronary syndromes:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>ST-elevation myocardial infarction (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Adjunct to percutaneous coronary intervention: </i>see <b>Percutaneous coronary intervention </b>for dosing guidance.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Adjunct to fibrinolysis</i>: <b>IV:</b> Bolus 60 units/kg (maximum: 4,000 units), followed by 12 units/<b>kg</b>/hour (maximum: 1,000 units/hour); adjust infusion rate to maintain anticoagulation target based on institutional protocol; continue for ≥48 hours or until revascularization (if performed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23256914','lexi-content-ref-16537665','lexi-content-ref-12847070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23256914','lexi-content-ref-16537665','lexi-content-ref-12847070'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>No planned reperfusion</i>: <b>IV:</b> Bolus 50 to 70 units/kg (maximum: 5,000 units), followed by 12 units/<b>kg</b>/hour; adjust infusion rate to maintain anticoagulation target based on institutional protocol; continue for ≥48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Non-ST-elevation acute coronary syndromes (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Ischemia-guided (conservative) approach (alternative agent)</i>:<b> IV:</b> Bolus 60 units/kg (maximum: 5,000 units), followed by 12 units/<b>kg</b>/hour (maximum: 1,000 units/hour); adjust infusion rate to maintain anticoagulation target based on institutional protocol; continue for ≥48 hours or until management changes to an invasive strategy (eg, percutaneous coronary intervention [PCI]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25249585','lexi-content-ref-9250846','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-15238590','lexi-content-ref-17124018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25249585','lexi-content-ref-9250846','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-15238590','lexi-content-ref-17124018'])">Ref</a></span>); if PCI is performed, see <b>Percutaneous coronary intervention </b>for dosing guidance.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Invasive approach (adjunct to percutaneous coronary intervention): </i>see <b>Percutaneous coronary intervention </b>for dosing guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Percutaneous</b>
<b> coronary intervention (off-label use):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>No prior anticoagulant therapy:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>No planned glycoprotein IIb/IIIa inhibitor use</i>: <b>IV:</b> Initial bolus of 70 to 100 units/kg (maximum: 10,000 units) to achieve activated clotting time (ACT) of 250 to 300 seconds (goal ACT may vary depending on point-of-care device); repeat bolus as needed to maintain goal ACT throughout procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.1','lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.1','lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Planned glycoprotein IIb/IIIa inhibitor use</i>: <b>IV:</b> Initial bolus of 50 to 70 units/kg (maximum: 7,000 units) to achieve ACT of 200 to 250 seconds (regardless of point-of-care device); repeat bolus as needed to maintain goal ACT throughout procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.1','lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.1','lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Prior anticoagulant therapy:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Prior anticoagulation with <b>heparin</b>:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>No planned glycoprotein IIb/IIIa inhibitor use</i>: <b>IV:</b> Check ACT prior to PCI and administer heparin bolus as needed (eg, 2,000 to 5,000 units) to achieve ACT of 250 to 300 seconds (goal ACT may vary depending on point-of-care device); repeat bolus (maximum: 10,000 units) as needed to maintain goal ACT throughout procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Planned glycoprotein IIb/IIIa inhibitor use</i>: <b>IV:</b> Check ACT prior to PCI and administer heparin bolus as needed (eg, 2,000 to 5,000 units) to achieve ACT of 200 to 250 seconds (regardless of point-of-care device); repeat bolus (maximum 7,000 units) as needed to maintain goal ACT throughout procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prior anticoagulation with <b>enoxaparin</b>:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If <i>percutaneous coronary intervention</i> occurs </i>
<b>
<i>≤12 hours</i></b>
<i> after the last SUBQ dose of enoxaparin</i>: Transition to unfractionated heparin is not recommended. Refer to enoxaparin monograph for dosing recommendations.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If percutaneous coronary intervention occurs </i>
<b>
<i>&gt;12 hours</i></b>
<i> after the last SUBQ dose of enoxaparin</i>: May use unfractionated heparin; refer to recommendations above for PCI with no prior anticoagulant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prior anticoagulation with <b>fondaparinux</b>:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>No planned glycoprotein IIb/IIIa inhibitor use</i>: <b>IV:</b> Initial bolus of 85 units/kg (maximum: 10,000 units) to achieve ACT of 250 to 300 seconds (goal ACT may vary depending on point-of-care device); repeat bolus as needed to maintain goal ACT throughout procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-20805623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-20805623'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Planned glycoprotein IIb/IIIa inhibitor use</i>: <b>IV:</b> Initial bolus of 60 units/kg (maximum: 7,000 units) to achieve ACT of 200 to 250 seconds (regardless of point-of-care device); repeat bolus as needed to maintain goal ACT throughout procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-20805623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.2020.2','lexi-content-ref-20805623'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc7d3bfb-f955-41a4-8a35-cea93abd84fe">Mechanical heart valve, bridging anticoagulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mechanical heart valve, bridging anticoagulation (for interruptions in warfarin therapy) (off-label use): Note:</b> Bridging during intervals of subtherapeutic anticoagulation should be considered for patients with mechanical mitral, tricuspid, or pulmonary valve replacement; however, for patients with mechanical aortic valve replacement, bridging is not required unless an additional thromboembolic risk factor is present or patient has an older-generation mechanical aortic valve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332150'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Limited data available: Initial: 18 units/<b>kg</b>/hour (no bolus) starting when INR falls below the therapeutic range; adjust infusion rate to maintain anticoagulation target based on institutional protocol. If patient is to undergo an invasive procedure, discontinue heparin 4 to 6 hours prior to procedure; reinitiate heparin infusion ≥24 hours after the procedure when bleeding risk is acceptable. Continue heparin until warfarin has been reinitiated and INR is within therapeutic range for 2 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315266','lexi-content-ref-Nkomo.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315266','lexi-content-ref-Nkomo.2023'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab176aec-622a-4f43-a5a1-4e407228963b">Mechanical heart valve, postsurgical management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mechanical heart valve, postsurgical management (to transition to warfarin) (off-label use): Note:</b> Initiate postoperatively when risk of bleeding is acceptable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315272','lexi-content-ref-Gaasch.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315272','lexi-content-ref-Gaasch.2019a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Limited data available: Initial: 12 to 18 units/<b>kg</b>/hour (no bolus); adjust infusion rate to maintain anticoagulation target based on institutional protocol. Overlap with warfarin until INR is stable and within therapeutic range for ≥2 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaasch.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaasch.2019a'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c2fc34c-fc82-40d1-bd60-e5be8b47e49e">Peripheral arterial occlusion, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral arterial occlusion, acute (off-label use):</b>
<b>Note:</b> Specific dosing information is limited, but anticoagulation is commonly used at the time of diagnosis to limit thrombus propagation while the patient is evaluated for other possible interventions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27840333','lexi-content-ref-Braun.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27840333','lexi-content-ref-Braun.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial bolus of 60 to 80 units/kg, followed by an initial continuous infusion of 12 to 18 units/<b>kg</b>/hour; adjust infusion rate to maintain anticoagulation target based on institutional protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315264','lexi-content-ref-Dager.2018','lexi-content-ref-Hull.2022.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315264','lexi-content-ref-Dager.2018','lexi-content-ref-Hull.2022.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9a047b1-b986-48a3-abb0-5ccd3dd3f7c9">Venous thromboembolism prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism prophylaxis (alternative agent): Note: </b>Low-weight patients (eg, &lt;50 kg) may be more sensitive to routine prophylactic doses, increasing the potential for higher than intended levels of anticoagulation; consider adhering to every-12-hour dosing interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Medical patients with acute illness at moderate to high risk for venous thromboembolism</i>: SUBQ:</b> 5,000 units every 8 to 12 hours; continue for length of hospitalization or until fully ambulatory (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315261','lexi-content-ref-31381464','lexi-content-ref-Pai.2019.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315261','lexi-content-ref-31381464','lexi-content-ref-Pai.2019.1'])">Ref</a></span>); extended prophylaxis beyond acute hospital stay is not routinely recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315261','lexi-content-ref-33861298','lexi-content-ref-22863355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315261','lexi-content-ref-33861298','lexi-content-ref-22863355'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Nonorthopedic surgery: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Patients with active cancer:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ:</b> 5,000 units 2 to 4 hours <i>prior to</i> surgery, then 5,000 units every 8 hours thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31381464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31381464'])">Ref</a></span>) <b>or</b> 5,000 units every 8 to 12 hours started ~6 to 24 hours <i>after</i> surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.2021'])">Ref</a></span>).<b> Note:</b> The optimal duration of prophylaxis has not been established, but it is usually given for a minimum of 7 to 10 days; extending for up to 4 weeks may be reasonable in those undergoing major abdominal or pelvic surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31381464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31381464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients without cancer:<b> Note:</b> For patients with moderate or high risk of venous thromboembolism (VTE) and low risk of bleeding.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ:</b> 5,000 units every 8 to 12 hours, with initial dose given ≥2 hours prior to surgery. Alternatively, may postpone pharmacologic prophylaxis until after surgery (eg, high bleeding risk) when it is safe to initiate. Continue until fully ambulatory and risk of VTE has diminished (typically up to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315263','lexi-content-ref-Pai.2019.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315263','lexi-content-ref-Pai.2019.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Orthopedic surgery (eg, hip fracture surgery, total hip arthroplasty, total knee arthroplasty)</i>:</b>
<b>SUBQ:</b> 5,000 units every 8 to 12 hours, with initial dose administered ≥12 hours preoperatively or ≥12 hours postoperatively once hemostasis is achieved; optimal duration of prophylaxis is unknown, but it is usually given for a minimum of 10 to 14 days and can be extended for up to 35 days; some experts suggest a duration in the lower end of the range (10 to 14 days) for total knee arthroplasty or higher end of the range (~30 days) for total hip arthroplasty (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265','lexi-content-ref-Pai.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265','lexi-content-ref-Pai.2020'])">Ref</a></span>). For extended duration of prophylaxis, may transition to an oral anticoagulant or alternative SUBQ anticoagulant with less frequent dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Pregnancy</i>: Note:</b> Dose intensity is individualized based on risk of thrombosis and bleeding complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylactic dose (also referred to as intermediate dose to account for weight gain during pregnancy):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>First trimester:</i>
<b>SUBQ:</b> 5,000 to 7,500 units every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Second trimester:</i>
<b>SUBQ:</b> 7,500 to 10,000 units every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Third trimester:</i>
<b>SUBQ:</b> 10,000 units every 12 hours (reduce dose if the aPTT becomes elevated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adjusted dose (therapeutic):</i>
<b>Note:</b> For patients at the highest risk of developing VTE (eg, history of recurrent thrombosis, severe thrombophilia), especially those who are receiving long-term therapy with an oral anticoagulant prior to pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ:</b> 10,000 units every 12 hours; adjust dose to target an aPTT of 1.5 to 2.5 times control, measured 6 hours after injection; monitor aPTT once daily until stable and within therapeutic range, then monitor every 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Management around labor and delivery</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Prior to delivery:</i> Discontinue heparin at the onset of spontaneous labor. Prior to planned induction of labor or cesarean delivery, discontinue heparin ≥12 hours before in patients receiving 7,500 to 10,000 units every 12 hours or ≥24 hours before in patients receiving &gt;10,000 units/dose, &gt;20,000 units/day, or an adjusted therapeutic dose. Consider checking coagulation parameters before delivery. Appropriate discontinuation is particularly important if neuraxial anesthesia is planned (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Postpartum</i>
<i>:</i> In patients at high risk of VTE who require an adjusted therapeutic dose, may restart ≥4 to 6 hours after vaginal delivery or ≥6 to 12 hours after cesarean delivery unless significant bleeding occurred or traumatic neuraxial catheter placement. For patients who require lower VTE prophylaxis doses (eg, patients not receiving an adjusted therapeutic dose during pregnancy) or those without an acute VTE, restart prophylaxis 6 to 12 hours after vaginal delivery and 12 to 24 hours after cesarean delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>). Anticoagulation should continue for up to 6 weeks postpartum, but potentially longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90a9bc2f-3de7-4ff3-99f1-ed0d68541f45">Venous thromboembolism treatment, deep vein thrombosis and/or pulmonary embolism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism treatment, deep vein thrombosis and/or pulmonary embolism: Note:</b> IV heparin may be preferred for initial therapy in patients who are hemodynamically unstable, may need invasive procedures or thrombolysis due to extensive clot burden, are obese, have renal failure, or when rapid reversal of anticoagulation may be needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lip.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lip.2022'])">Ref</a></span>). If thrombolytics are used, it is recommended to discontinue heparin during administration then resume upon completion of the thrombolytic infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33007077','lexi-content-ref-Tapson.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33007077','lexi-content-ref-Tapson.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inpatient treatment:</i>
<b>IV:</b> Initial: 80 units/kg bolus followed by a continuous infusion of 18 units/<b>kg</b>/hour <b>or </b>5,000 unit bolus followed by 1,333 units/hour; adjust infusion rate to maintain target laboratory values based on institutional protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315264'])">Ref</a></span>). <b>Note:</b> Weight-based dosing is more effective than fixed dosing at reaching therapeutic anticoagulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315264','lexi-content-ref-8124829','lexi-content-ref-11176764','lexi-content-ref-Dager.2018','lexi-content-ref-22531940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315264','lexi-content-ref-8124829','lexi-content-ref-11176764','lexi-content-ref-Dager.2018','lexi-content-ref-22531940'])">Ref</a></span>).</p>
<table border="1" data-table-id="epopros" frame="border" rules="all">
<caption>
<b>Example Weight-Based IV Heparin Nomogram for Treatment of Venous Thromboembolism<sup>a,b</sup></b></caption>
<colgroup><col align="center"/>
<col/>
<col/>
<col align="center"/>
</colgroup><tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup>Hull 2022a</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>b</sup>This is one example of a weight-based heparin dosing nomogram. Each institution should establish their own heparin dosing nomogram. Other heparin nomograms based on aPTT or anti-Factor Xa monitoring may be employed. Therapeutic range for aPTT must be established at each individual laboratory (Dager 2018).</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>c</sup>Use actual body weight for calculations.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">
<b>Initial dose and monitoring</b></p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">→</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">80 units/<b>kg</b> bolus (maximum dose: 10,000 units)<sup>c</sup>, then 18 units/<b>kg</b>/hour (maximum initial infusion: 2,000 units/hour)<sup>c</sup></p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Obtain aPTT 6 hours after initial heparin bolus</p></td></tr>
<tr>
<td align="center" colspan="4" valign="middle">
<p style="text-indent:0em;">
<b>Dosing adjustments and monitoring</b></p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">
<b>If using anti-Factor Xa activity (units/mL)</b></p></td>
<td align="center" colspan="2" valign="middle">
<p style="text-indent:0em;">
<b>Response</b></p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">
<b>If using aPTT (seconds)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0 to 0.09</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• Bolus 25 units/<b>kg</b></p>
<p style="text-indent:-2em;margin-left:2em;">• Increase infusion by 3 units/<b>kg</b>/hour</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay in 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">&lt;40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.1 to 0.19</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• Increase infusion by 2 units/<b>kg</b>/hour</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay in 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">40 to 49</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.2 to 0.29</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• Increase infusion by 1 unit/<b>kg/</b>hour</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay in 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">50 to 69</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.3 to 0.7</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• No change (within therapeutic range)</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay in 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">• Once therapeutic for 2 consecutive assays, may change to once-daily assays</p></td>
<td align="center">
<p style="text-indent:0em;">70 to 110</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.71 to 0.79</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• Decrease infusion by 1 unit/<b>kg</b>/hour</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay in 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">111 to 120</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.8 to 0.89</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• Stop infusion for 1 hour, then decrease by 2 units/<b>kg</b>/hour</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay 6 hours after restarting the infusion</p></td>
<td align="center">
<p style="text-indent:0em;">121 to 130</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.9 to 0.99</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• Stop infusion for 1 hour, then decrease by 3 units/<b>kg</b>/hour</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay 6 hours after restarting the infusion</p></td>
<td align="center">
<p style="text-indent:0em;">131 to 140</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1 to 1.09</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• Stop infusion for 2 hours, then decrease by 4 units/<b>kg</b>/hour</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay 6 hours after restarting the infusion</p></td>
<td align="center">
<p style="text-indent:0em;">141 to 150</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥1.1</p></td>
<td align="left" colspan="2">
<p style="text-indent:-2em;margin-left:2em;">• Stop infusion for 2 hours, then decrease by 5 units<b>/kg</b>/hour and notify clinician</p>
<p style="text-indent:-2em;margin-left:2em;">• Repeat assay 6 hours after restarting the infusion</p></td>
<td align="center">
<p style="text-indent:0em;">&gt;150</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Outpatient treatment:</i>
<b>Note:</b> Alternative for patients who have a contraindication to other anticoagulants.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> Initial: 333 units/kg, followed by 250 units/kg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315257','lexi-content-ref-22315259','lexi-content-ref-Lip.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315257','lexi-content-ref-22315259','lexi-content-ref-Lip.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pregnancy (therapeutic, adjusted dose):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> Initial: 10,000 units every 12 hours; adjust dose to target an aPTT of 1.5 to 2.5 times control, measured 6 hours after injection; monitor aPTT once daily until stable and within therapeutic range, then monitor every 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Management around labor and delivery</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prior to delivery:</i> Discontinue heparin at the onset of spontaneous labor. Prior to planned induction of labor or cesarean delivery, discontinue heparin ≥24 hours before in patients receiving a therapeutic adjusted dose of heparin. Consider checking coagulation parameters before delivery. Appropriate discontinuation is particularly important if neuraxial anesthesia is planned (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Bauer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postpartum:</i> May restart ≥4 to 6 hours after vaginal delivery or ≥6 to 12 hours after cesarean delivery, unless significant bleeding occurred or traumatic neuraxial catheter placement. Optimal duration of anticoagulation is unknown. In general, total duration of anticoagulation (antepartum plus postpartum) should be at least 3 to 6 months with at least 6 weeks postpartum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Malhotra.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315276','lexi-content-ref-29939938','lexi-content-ref-Malhotra.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning between anticoagulants:</b>
<b> Note: </b>This provides general guidance on transitioning between anticoagulants; also refer to local protocol for additional detail.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from another anticoagulant to IV heparin:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from a therapeutic dose of SUBQ low-molecular-weight heparin or SUBQ fondaparinux to a therapeutic dose of IV heparin:</i> Start IV heparin without a bolus dose (infusion rate depends on the indication) 1 to 2 hours before the next dose of low-molecular-weight heparin (LMWH) or fondaparinux would have been due (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from warfarin to a therapeutic dose of IV heparin:</i> Stop warfarin and, when INR is as close as possible to the lower end of the targeted INR range, start IV heparin without a bolus dose (infusion rate depends on the indication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from a direct-acting oral anticoagulant to a therapeutic dose of IV heparin: </i>Stop direct-acting oral anticoagulant (DOAC) and, when the next DOAC dose would have been due, start IV heparin without a bolus dose (infusion rate depends on the indication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from IV heparin to another anticoagulant:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from a therapeutic dose of IV heparin to therapeutic SUBQ low-molecular-weight heparin or SUBQ fondaparinux: </i>Stop IV heparin and within 1 hour start SUBQ LMWH or SUBQ fondaparinux. <b>Note:</b> If aPTT is not within therapeutic range at the time heparin is stopped, consult local protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from a therapeutic dose of IV heparin to warfarin:</i> Start warfarin and continue IV heparin until INR is within therapeutic range (Dager 2018; Hull 2022a). <b>Note:</b> Overlap IV heparin with warfarin until INR is ≥2 for at least 2 measurements taken ~24 hours apart (duration of overlap is ~5 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269','lexi-content-ref-Hull.2022.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269','lexi-content-ref-Hull.2022.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from a therapeutic dose of IV heparin to a direct-acting oral anticoagulant:</i> Start DOAC when the heparin infusion is stopped (consult local protocol if the aPTT is above the target range) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990423"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b>
<b>IV, SUBQ:</b> Mild to severe impairment: No initial dosage adjustment necessary; adjust to maintain anticoagulation target based on institutional protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20727512','lexi-content-ref-6993082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20727512','lexi-content-ref-6993082'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal replacement therapies:</b> Poorly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nemecek.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nemecek.2019'])">Ref</a></span>): <b>IV, SUBQ:</b> No supplemental dose or initial dosage adjustment necessary in patients receiving renal replacement therapies (eg, hemodialysis, peritoneal dialysis, CRRT, PIRRT); adjust to maintain anticoagulation target based on institutional protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25951901','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25951901','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987595"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Factor Xa activity.</p></div>
<div class="block arsc drugH1Div" id="F58873708"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Major bleeding</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Heparin increases the risk of bleeding (<b>hemorrhage</b>), including major bleeding. Bleeding may occur at any site and may be severe enough to be life-threatening, with reports of fatal cases (eg, intracranial bleeding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20868290','lexi-content-ref-10927736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20868290','lexi-content-ref-10927736'])">Ref</a></span>). Bleeding is reversible with the use of protamine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; binds to antithrombin III, increasing its activity 1,000-fold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11413093','lexi-content-ref-24801362','lexi-content-ref-20868290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11413093','lexi-content-ref-24801362','lexi-content-ref-20868290'])">Ref</a></span>). This complex inactivates factors IIa (thrombin), Xa, IXa, XIa, and XIIa, leading to decreased coagulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11413093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11413093'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any time but data show that it is more common toward the end of planned therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10927736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10927736'])">Ref</a></span>). Bleeding may occur sooner; however, this is largely driven by other risk factors for bleeding that are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20868290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20868290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Supratherapeutic dosing (excess bolus or infusion) or aPTT level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18657648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18657648'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20868290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20868290'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Uncontrolled and severe hypertension</p>
<p style="text-indent:-2em;margin-left:6em;">• History of hemorrhagic stroke</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent gastrointestinal bleed</p>
<p style="text-indent:-2em;margin-left:6em;">• Females</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;60 years</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent antiplatelet therapy (eg, P2Y12 inhibitors, GPIIb/IIIa inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20868290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20868290'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of thrombolytics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11413093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11413093'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Liver disease with impaired hemostasis</p>
<p style="text-indent:-2em;margin-left:6em;">• Ulcerative GI lesions</p>
<p style="text-indent:-2em;margin-left:6em;">• Continuous GI tube drainage</p>
<p style="text-indent:-2em;margin-left:6em;">• Subacute bacterial endocarditis</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent coagulation disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11413093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11413093'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent brain, spinal, or ophthalmic surgery</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent surgery, trauma, or invasive procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11413093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11413093'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Spinal interventions, including epidurals or spinal taps (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25899949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25899949'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Osteoporosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Studies primarily in patients who are pregnant show that heparin may cause significant <b>decreased bone mineral density </b>(BMD) ≥10% decrease from baseline femur measurements (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8141217','lexi-content-ref-17000242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8141217','lexi-content-ref-17000242'])">Ref</a></span>). A study in patients on hemodialysis showed decreases in BMD primarily in the lumbar spine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32520445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32520445'])">Ref</a></span>). BMD losses may still be significant 6 months after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8141217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8141217'])">Ref</a></span>). <b>Bone</b>
<b>fractures</b> are uncommon (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8815571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8815571'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose- and time-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25342997','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25342997','lexi-content-ref-31652944'])">Ref</a></span>); binds to osteoprotegerin, sterically inhibiting its interaction with RANKL on osteoblasts. This promotes RANK-RANKL linkages, activating osteoclasts and causing bone resorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15646699','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15646699','lexi-content-ref-31652944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; occurs after about 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17000242','lexi-content-ref-8178860','lexi-content-ref-26895998','lexi-content-ref-25342997','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17000242','lexi-content-ref-8178860','lexi-content-ref-26895998','lexi-content-ref-25342997','lexi-content-ref-31652944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses (15,000 to 30,000 units/day), but this is controversial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17000242','lexi-content-ref-8178860','lexi-content-ref-26161162','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17000242','lexi-content-ref-8178860','lexi-content-ref-26161162','lexi-content-ref-31652944'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term use of at least 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17000242','lexi-content-ref-8178860','lexi-content-ref-26895998','lexi-content-ref-25342997','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17000242','lexi-content-ref-8178860','lexi-content-ref-26895998','lexi-content-ref-25342997','lexi-content-ref-31652944'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of unfractionated heparin (versus low-molecular weight heparin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25342997','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25342997','lexi-content-ref-31652944'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17000242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17000242'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombocytopenia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mild<b> thrombocytopenia </b>may occur during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20059332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20059332'])">Ref</a></span>). <b>Heparin-induced thrombocytopenia</b> without thrombosis (HIT) or with thrombosis (HITT) may also occur, warranting discontinuation of therapy, and can be fatal without treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33267665','lexi-content-ref-20235296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33267665','lexi-content-ref-20235296'])">Ref</a></span>). HIT/HITT should be suspected if there is a 30% to 50% reduction in platelet count from baseline with or without new thrombosis formation while on heparin therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416511','lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416511','lexi-content-ref-32904403'])">Ref</a></span>). The 4T score can be used to evaluate the probability of HIT and whether to further pursue laboratory evaluation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482768','lexi-content-ref-16634744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482768','lexi-content-ref-16634744'])">Ref</a></span>). HIT/HITT antibodies resolve approximately 90 to 100 days after discontinuation of therapy; however, it is unknown if those with a history of HIT/HITT are more likely to develop the reaction again if re-exposed to heparin. Therefore, avoidance of heparin is recommended (or allowance of only short-term use for specific indications) even after resolution of antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-32904403'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Time-related; HIT is an immune-mediated complication where IgG antibodies directed at complexes of heparin and the platelet protein, platelet factor 4 (PF4), bind to the FcγIIa receptors on platelets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416511','lexi-content-ref-22315270','lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416511','lexi-content-ref-22315270','lexi-content-ref-32904403'])">Ref</a></span>). This causes platelet activation, aggregation, and significant thrombin generation, leading to thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416511','lexi-content-ref-22315270','lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416511','lexi-content-ref-22315270','lexi-content-ref-32904403'])">Ref</a></span>). Thrombocytopenia is secondary to the significant activation and usage of platelets, effectively removing them from circulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32904403'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; the decrease in platelet count typically occurs 5 to 10 days after heparin initiation; however, platelet count can fall within 24 hours after heparin initiation in “rapid-onset HIT,” which tends to occur in individuals with circulating heparin antibodies secondary to a recent exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-32904403'])">Ref</a></span>). “Delayed-onset HIT” is also possible, which occurs when platelet count fall occurs weeks after heparin is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416511','lexi-content-ref-22315270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416511','lexi-content-ref-22315270'])">Ref</a></span>). Thrombosis can precede thrombocytopenia in up to 25% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors for HIT:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer courses of heparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32904403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of unfractionated heparin (versus low molecular weight heparin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416511','lexi-content-ref-22315270','lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416511','lexi-content-ref-22315270','lexi-content-ref-32904403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Bovine heparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32904403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients undergoing surgery (particularly cardiac and orthopedic surgery) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-32904403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients presenting with major trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32904403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-32904403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-32904403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Additional risk factors for HITT:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High antibody levels (optical density or titer) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416511'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Marked thrombocytopenia (&gt;90% decline from baseline) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416511'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F178718"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac tamponade (Su 2005), vasospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Transient alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (Su 2005), suppression of aldosterone synthesis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism (Burke 1983)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (including adrenal hemorrhage, ovarian hemorrhage, retroperitoneal hemorrhage) (Krishnaswamy 2011), heparin-induced thrombocytopenia, thrombocytopenia, thrombosis in heparin-induced thrombocytopenia (including acute myocardial infarction, cerebral thrombosis, cerebrovascular accident, deep vein thrombosis, mesenteric thrombosis, peripheral gangrene, pulmonary embolism, renal artery thrombosis, skin necrosis)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Bottio 2003), hypersensitivity reaction (including pruritus and burning sensation of feet [plantar side]), infusion-related reaction (skin necrosis), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (SUBQ), hematoma at injection site (SUBQ), irritation at injection site (SUBQ), pain at injection site (SUBQ), skin ulceration at injection site (SUBQ), tissue necrosis at injection site (SUBQ)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Barbour 1994), decreased bone mineral density (Douketis 1996), osteoporosis (with long-term use) (Casele 2006)</p></div>
<div class="block coi drugH1Div" id="F178735"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to heparin or any component of the formulation (unless a life-threatening situation necessitates use and use of an alternative anticoagulant is not possible); severe thrombocytopenia; history of heparin-induced thrombocytopenia; history of heparin-induced thrombocytopenia with thrombosis; uncontrolled active bleeding (except when this is due to disseminated intravascular coagulation); not for use when appropriate blood coagulation tests cannot be obtained at appropriate intervals (applies to full-dose heparin only).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Some products contain benzyl alcohol as a preservative; their use in neonates, infants, or pregnant or breastfeeding patients is contraindicated by some manufacturers.</p></div>
<div class="block war drugH1Div" id="F178715"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heparin resistance: Dose requirements &gt;35,000 units/24 hours to maintain a therapeutic aPTT may occur in patients with antithrombin deficiency, increased heparin clearance, elevations in heparin-binding proteins, and elevations in factor VIII and/or fibrinogen; frequently encountered in patients with fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer, and in postsurgical patients; measurement of anticoagulant effects using anti-Factor Xa levels may be of benefit.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Elevations in serum aminotransferases have been observed during therapy. These elevations should be evaluated with caution as they may occur and resolve in the setting of the underlying condition for which heparin is being used.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including fever, chills, urticaria, asthma, rhinitis, lacrimation, and anaphylaxis, have been reported. In patients with a documented hypersensitivity reaction, heparin should only be considered in life-threatening situations when use of an alternative anticoagulant is not possible. Some products are derived from animal tissue and may be contraindicated in patients with animal allergies (ie, pork); consult individual prescribing information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol as a preservative. In neonates, large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome"); the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling. Use in neonates, infants, or pregnant or nursing mothers is contraindicated by some manufacturers; the use of preservative-free heparin is, therefore, recommended in these populations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfites: Some preparations contain sulfite which may cause allergic reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fatal medications errors: Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Clinicians <b>must</b> carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen; fatal hemorrhages have occurred related to heparin overdose especially in pediatric patients.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878481"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Confirm the concentration of all heparin injection vials prior to administration; do not use heparin injection as a "catheter lock flush" as the injection is supplied in various concentrations including highly concentrated strengths. Fatal hemorrhages have occurred in pediatric patients when higher concentrations of heparin injection were confused with lower concentrations of heparin lock flush.</p>
<p style="text-indent:0em;margin-top:2em;">Heparin-induced thrombocytopenia (HIT) has been reported in pediatric patients; incidence and risk factors are not well-defined due to variability related to patient inclusion and laboratory techniques; incidence rates up to 2.3% in PICU patients have been reported, and cases observed at both low and high levels of heparin exposure (eg, venous access device line flushes and supratherapeutic doses associated with hemodialysis and during cardiopulmonary bypass). Monitor platelet count closely; if HIT develops, consider alternate anticoagulation therapy (eg, danaparoid, argatroban) (ACCP [Monagle 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">Heparin resistance should be suspected in pediatric patients if unable to achieve an activated clotting time (ACT) &gt;300 seconds after administration of &gt;600 units/kg (ACCP [Giglia 2013]).</p></div>
<div class="block foc drugH1Div" id="F178727"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2000 units (1000 mL); 25,000 units (500 mL); 2000 units in 0.9% NaCl per liter (1000 mL); 25,000 units/500 mL (500 mL); 25,000 units/500 mL in NaCl 0.45% (500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2000 units in 0.9% NaCl per liter (1000 mL); 25,000 units/500 mL in NaCl 0.45% (500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 units/mL (1 mL, 10 mL, 30 mL); 5000 units/mL (1 mL, 10 mL); 5000 units/0.5 mL (0.5 mL); 10,000 units/mL (1 mL, 4 mL, 5 mL); 20,000 units/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 units/mL (2 mL); 5000 units/mL (1 mL); 5000 units/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 units (500 mL); 10,000 units (250 mL [DSC]); 12,500 units (250 mL [DSC]); 20,000 units (500 mL); 25,000 units (250 mL); 1 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL); 10 units/mL (1 mL, 3 mL [DSC], 5 mL, 10 mL); 100 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL); 1000 units/500 mL in NaCl 0.9% (500 mL); 12,500 units/250 mL in NaCl 0.45% (250 mL); 25,000 units/250 mL in Dextrose 5% (250 mL); 25,000 units/250 mL in NaCl 0.45% (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL); 100 units/mL (3 mL [DSC], 5 mL [DSC]); 25,000 units/250 mL in Dextrose 5% (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5000 units/0.5 mL (0.5 mL)</p></div>
<div class="block geq drugH1Div" id="F178711"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524629"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Heparin (Porcine) in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000UT/500ML 0.9% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000UNIT/L 0.9% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12500UT/250ML 0.45% (per mL): $0.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25000UT/250ML 0.45% (per mL): $0.04 - $0.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25000UT/500ML 0.45% (per mL): $0.02 - $0.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Heparin Na (Pork) Lock Flsh PF Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 units/mL (per mL): $1.16 - $1.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 units/mL (per mL): $1.00 - $1.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $1.03 - $1.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Heparin Sod (Porcine) in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40UNIT/ML 5% (per mL): $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $0.04 - $0.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25000UT/500ML 5% (per mL): $0.02 - $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Heparin Sod (Pork) Lock Flush Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 units/mL (per mL): $0.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $0.19 - $0.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Heparin Sodium (Porcine) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 units/mL (per mL): $0.27 - $0.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 units/mL (per mL): $1.45 - $5.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 units/mL (per mL): $2.52 - $9.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 units/mL (per mL): $12.00 - $20.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Heparin Sodium (Porcine) PF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 units/0.5 mL (per 0.5 mL): $2.64 - $7.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 units/mL (per mL): $7.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Heparin Sodium (Porcine) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 units/0.5 mL (per 0.5 mL): $3.72 - $3.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867108"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25,000 units/500 mL (500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 units/mL (1 mL, 2 mL, 10 mL, 30 mL); 10,000 units/mL (0.5 mL, 1 mL, 5 mL); 1000 units (500 mL, 1000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20,000 units/500 mL in Dextrose 5% (500 mL); 100 units/mL (2 mL, 10 mL); 25,000 units/250 mL in Dextrose 5% (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5000 units/0.5 mL (0.5 mL)</p></div>
<div class="block adip drugH1Div" id="F53567012"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;text-align:justify;display:inline">Updates to the United States Pharmacopeia (USP) heparin monograph were made in response to over 200 deaths linked to contaminated heparin products in 2007-2008. Serious adverse effects (including hypersensitivity reactions) were associated with a heparin-like contaminant (oversulfated chondroitin sulfate). At the time, the available quality assurance tests did not test for oversulfated chondroitin sulfate. Effective October 1, 2009, a new reference standard for heparin and a new test to determine potency (the chromogenic antifactor IIa test) were established by USP. The updated USP heparin monograph also harmonized the USP unit with the WHO international standard (IS) unit (ie, international unit). The new standard may result in a 10% reduction in potency for heparin marketed in the United States. The FDA has requested that all manufacturers differentiate (from "old" heparin products) heparin products manufactured by the new standards. The labels of products manufactured according to the new standard will have an "N" in the lot number or following the expiration date. Additionally, products manufactured by Hospira may be identified by the number "82" or higher (eg, 83, 84) at the beginning of their lot numbers. For therapeutic use, practitioners may or may not notice that larger doses of heparin are required to achieve "therapeutic" activity of anticoagulation. The impact of this change in potency should be less significant when heparin is administered by subcutaneous injection due to low and variable bioavailability. Heparin dosing should always be individualized according to the patient-specific clinical situation. Appropriate clinical judgment is essential in determining heparin dosage (Smythe 2010). </p></div>
<div class="block admp drugH1Div" id="F52612973"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Many concentrations of heparin are available and range from 1 to 20,000 units/mL. Carefully examine each prefilled syringe, bag, or vial prior to use to ensure that the correct concentration is chosen.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do <b>not</b> administer IM due to pain, irritation, and hematoma formation.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">IV bolus: Administered over 10 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Infuse via infusion pump.</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin lock: Inject via injection cap using positive pressure flushing technique. Heparin lock flush solution is intended only to maintain patency of IV devices and is <b>not</b> to be used for anticoagulant therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Central venous catheters: Must be flushed with heparin solution when newly inserted, daily (at the time of tubing change), after blood withdrawal or transfusion, and after an intermittent infusion through an injectable cap.</p>
<p style="text-indent:-2em;margin-left:4em;">SubQ: Not all preparation intended for SubQ administration, verify product selection. Inject in subcutaneous tissue only (not muscle tissue). Injection sites should be rotated (usually left and right portions of the abdomen, above iliac crest).</p></div>
<div class="block adm drugH1Div" id="F178732"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Inject in subcutaneous tissue only (not muscle tissue). Injection sites should be rotated (usually left and right portions of the abdomen, above iliac crest).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Do not administer IM due to pain, irritation, and hematoma formation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Continuous IV infusion:</b> Infuse via infusion pump. If preparing solution, mix thoroughly prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Catheter patency maintenance:</p>
<p style="text-indent:-2em;margin-left:4em;">Heparin lock: Inject via injection cap using positive pressure flushing technique. Heparin lock flush solution is intended only to maintain patency of IV devices and is <b>not</b> to be used for anticoagulant therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Heparin premix bag: Administer at 6 units per hour through IV catheter to maintain patency; <b>not</b> to be used for anticoagulant therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Central venous catheters: Must be flushed with heparin solution when newly inserted, daily (at the time of tubing change), after blood withdrawal or transfusion, and after an intermittent infusion through an injectable cap. A volume of at least 10 mL of blood should be removed and discarded from a heparinized line before blood samples are sent for coagulation testing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravesical</b> (off-label use): Various dosage regimens of heparin (20,000 to 50,000 units) alone or with alkalinized lidocaine (1% to 4%) have been instilled into the bladder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-arterial</b> (off-label use): Infuse via infusion pump. If preparing solution, mix thoroughly prior to administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17576891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17576891'])">Ref</a></span>).</p></div>
<div class="block uicn drugH1Div" id="F14472659"><span class="drugH1">Usual Infusion Concentrations: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> Maintenance of line patency: 0.5 unit/mL</p></div>
<div class="block uicp drugH1Div" id="F14472658"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 100 units/mL</p></div>
<div class="block sts drugH1Div" id="F178745"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Heparin solutions are colorless to slightly yellow. Minor color variations do not affect therapeutic efficacy. Heparin should be stored at room temperature. Protect from freezing and temperatures &gt;40°C.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Stability at room temperature and refrigeration:</p>
<p style="text-indent:-2em;margin-left:4em;">Prepared bag: Variable (specific to solution, concentration, and/or study conditions); also refer to manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Premixed bag: After seal is broken, 4 days; also refer to manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Out of overwrap stability: 30 days; also refer to manufacturer's labeling.</p></div>
<div class="block usep drugH1Div" id="F53567184"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Systemic: Injection: Prophylaxis and treatment of thromboembolic disorders and anticoagulant for blood transfusions, extracorporeal circulation, and dialysis procedures (FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Heparin lock flush solution: Maintain patency of IV devices (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F178805"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Heparin may be confused with Hespan</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">National Patient Safety Goals:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have approved protocols and evidence-based practice guidelines in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes medication selection, dosing (including adjustments for age, renal function, or liver function), drug-drug interactions, drug-food interactions, other applicable risk factors, monitoring, patient and family education, proper administration, reversal of anticoagulation, management of bleeding events, and perioperative management. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism during procedures or hospitalizations (NPSG.03.05.01).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The 100 unit/mL concentration should not be used to flush heparin locks, IV lines, or intra-arterial lines in neonates or infants &lt;10 kg (systemic anticoagulation may occur). The 10 unit/mL flush concentration may inadvertently cause systemic anticoagulation in infants &lt;1 kg who receive frequent flushes.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Heparin sodium injection 10,000 units/mL and Hep-Lock U/P 10 units/mL have been confused with each other. Fatal medication errors have occurred between the two whose labels are both blue. <b>Never rely on color as a sole indicator to differentiate product identity.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Labeling changes: Effective May 1, 2013, heparin labeling is required to include the total amount of heparin per vial (rather than only including the amount of heparin per mL). During the transition, hospitals should consider only stocking the newly labeled heparin to avoid potential errors and confusion with the older labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Heparin lock flush solution is intended only to maintain patency of IV devices and is <b>not</b> to be used for anticoagulant therapy.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299438"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F178720"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Andexanet Alfa (Coagulation Factor Xa [Recombinant], Inactivated): May diminish the therapeutic effect of Heparin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Heparin may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Heparin may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithrombin: May enhance the anticoagulant effect of Heparin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticorelin: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with other anticoagulants prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the adverse/toxic effect of Heparin. Specifically, the risk of bleeding may be increased. Management: Use caution and reduce the dose of heparin or dipyridamole if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Heparin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Heparin may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Landiolol: Heparin may enhance the hypotensive effect of Landiolol. Heparin may decrease the serum concentration of Landiolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Heparin may decrease the serum concentration of Levothyroxine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: May diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oritavancin: May diminish the therapeutic effect of Heparin. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: Heparin may increase the serum concentration of Palifermin.  Management: If heparin is used to maintain an intravenous line, rinse the line with saline prior to and after palifermin administration.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the anticoagulant effect of Heparin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Heparin may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.  Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Streptokinase: May enhance the anticoagulant effect of Heparin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telavancin: May diminish the therapeutic effect of Heparin. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Heparin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F6481836"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Heparin does not cross the placenta (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, the risk of thromboembolism is increased during pregnancy and the immediate postpartum period. Heparin may be used for anticoagulation in pregnancy (ACOG 2018). Due to a better safety profile and ease of administration, the use of low molecular weight heparin (LMWH) is generally preferred over heparin (unfractionated heparin [UFH]) in pregnancy (ACOG 2018; Bates 2018; ESC [Regitz-Zagrosek 2018]); however, heparin may be preferred in pregnant patients with kidney dysfunction (Bates 2018). Anticoagulant therapy for the prevention and treatment of thromboembolism in pregnant patients can be discontinued prior to induction of labor or a planned cesarean delivery (Bates 2018) or LMWH can be converted to UFH in higher risk patients (ESC [Regitz-Zagrosek 2018]). Consult current recommendations for appropriate use in pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Patients with mechanical heart valves have an increased risk of adverse maternal and fetal outcomes and these risks are greater without appropriate anticoagulation. UFH or LMWH may be used in pregnant patients with mechanical heart valves. Increased monitoring is required to maintain adequate therapeutic concentrations during pregnancy (consult current recommendations for details) (ESC [Regitz-Zagrosek 2018]; ACC/AHA [Otto 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Some products contain benzyl alcohol as a preservative; their use in pregnant patients is contraindicated by some manufacturers; use of a preservative-free formulation is recommended.</p></div>
<div class="block mopp drugH1Div" id="F53567143"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hemoglobin, hematocrit, signs of bleeding; fecal occult blood test; aPTT (or antifactor Xa activity levels) or activated clotting time (ACT) depending upon indication. Thromboelastogram (TEG) may be useful in monitoring overall hemostasis and fibrinolysis in patients receiving unfractionated heparin for therapeutic anticoagulation (AHA [Giglia 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Platelet counts should be routinely monitored (eg, every 2 to 3 days on days 4 to 14 of heparin therapy) when the risk of heparin‐induced thrombocytopenia (HIT) is &gt;1% (eg, receiving therapeutic dose heparin, postoperative antithrombotic prophylaxis), if the patient has received heparin or low molecular weight heparin (eg, enoxaparin) within the past 100 days, if preexposure history is uncertain, or if anaphylactoid reaction to heparin occurs. When the risk of HIT is &lt;1% (eg, medical/obstetrical patients receiving heparin flushes), routine platelet count monitoring is not recommended (ACCP [Guyatt 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">For patients on extracorporeal membrane oxygenation (ECMO), ACT should be checked hourly while patient is on ECMO (AHA [Giglia 2013]).</p></div>
<div class="block rerp drugH1Div" id="F53567011"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Venous thromboembolism: Heparin: pediatric patients: 0.35 to 0.7 unit/mL; adults: 0.3 to 0.7 unit/mL anti-Xa activity (by chromogenic assay) or 0.2 to 0.4 unit/mL (by protamine titration); aPTT: 1.5 to 2.5 times control (usually reflects an aPTT of 60 to 85 seconds) (Garcia 2012; ACCP [Monagle 2012])</p>
<p style="text-indent:-2em;margin-left:2em;">ECMO anticoagulation: Maintain the ACT between 180 and 220 seconds; additional monitoring targets for heparin therapy are prolongation of the PTT to 1.5 to 2.5 times the control value and an anti-Xa level of 0.3 to 0.7 units/mL (AHA [Giglia 2013])</p></div>
<div class="block pha drugH1Div" id="F178714"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Potentiates the action of antithrombin III and thereby inactivates thrombin (as well as other coagulation factors IXa, Xa, XIa, XIIa, and plasmin) and prevents the conversion of fibrinogen to fibrin; heparin also stimulates release of lipoprotein lipase (lipoprotein lipase hydrolyzes triglycerides to glycerol and free fatty acids)</p></div>
<div class="block phk drugH1Div" id="F178734"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Increased interpatient variability of pharmacokinetic parameters in pediatric patients compared to adults; however, age-related decreases in volume of distribution and clearance with increasing pediatric patient age have been reported (ACCP [Monagle 2012]; McDonald 1981).</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Anticoagulation: IV: Immediate; SUBQ: ~20 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral, rectal: Erratic at best from these routes of administration; SUBQ absorption is also erratic, but considered acceptable for prophylactic use.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Premature neonates (data based on single dose of 100 units/kg within 4 hours of birth) (McDonald 1981): Inversely proportional to gestational age (GA).</p>
<p style="text-indent:-2em;margin-left:6em;">GA 25 to 28 weeks: 81 ± 41 mL/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 29 to 32 weeks: 73.3 ± 24.8 mL/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 33 to 36 weeks: 57.8 ± 32.2 mL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Following a single 75 unit/kg dose: 36.6 ± 7.4 mL/kg (McDonald 1981).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Complex; thought to occur by depolymerization and desulphation via the reticuloendothelial system primarily in the liver and spleen (ACCP [Garcia 2012]; Dawes 1979; Estes 1980; Kandrotas 1992).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Age-related: Shorter half-life reported in premature neonates compared to adult patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Premature neonates GA 25 to 36 weeks (data based on single dose of 100 units/kg within 4 hours of birth): Mean range: 35.5 to 41.6 minutes (McDonald 1981).</p>
<p style="text-indent:-2em;margin-left:4em;">Dose-dependent: IV bolus: 25 units/kg: 30 minutes (Bjornsson 1982); 100 units/kg: 60 minutes (de Swart 1982); 400 units/kg: 150 minutes (Olsson 1963).</p>
<p style="text-indent:-2em;margin-left:4em;">Mean: 1.5 hours; Range: 1 to 2 hours; affected by obesity, renal function, malignancy, presence of pulmonary embolism, and infections.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> At therapeutic doses, elimination occurs rapidly via nonrenal mechanisms. With very high doses, renal elimination may play more of a role; however, dosage adjustment remains unnecessary for patients with renal impairment (Kandrotas 1992).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (small amounts as unchanged drug); <b>Note: </b>At therapeutic doses, elimination occurs rapidly via nonrenal mechanisms. With very high doses, renal elimination may play more of a role; however, dosage adjustment remains unnecessary for patients with renal impairment (Kandrotas 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Age-related changes; within neonatal population, slower clearance with lower GA; however, when compared to adults, the overall clearance in neonatal and pediatric patients is faster than adults (ACCP [Monagle 2012 ]; McDonald 1981).</p></div>
<div class="block phksp drugH1Div" id="F51196159"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The half-life may be increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The half-life may be increased or decreased.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma levels may be higher.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F178738"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Heparin leo | Hikma heparin | Liquemin | Multiparin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Heparina | Heparina duncan | Heparina gemepe | Heparina sodica | Riveparin-heparina rivero | Sobrius | Sodiparin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Heparin gilvasan | Heparin immuno | Ivorat anti-xa | Liquemin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Heparin sodium chloride | Heparinised Saline</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Heparon</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Calparine | Heparine | Heparine leo | Heparine natrium b.braun | Heparine novo-nordisk | Liquemine</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Heparine medis | Sakarin 25000</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Heparin na</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Actparin | Cellparin | Hepamax s | Heparin | Heparina sodica | Heptar | Liquemine | Parinex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Heparin | Heparin bichsel | Heparin fresenius | Heparin kabi | Heparin na | Heparin novonordisk | Heparine choay | Liquemin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Pan heparine | Sakarin 25000</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Heparina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Heparin sod.</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Hepamax s | Heparina | Heparina northia | Heparina sodica | Inhepar | Liquemine</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Calciparin | Calciparine | Calcium Heparin Sanofi-Aventis | Heparin | Heparin Natrium | Heparin-calcium | Liquemin | Liquemin n | Thrombophob | Vetren</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hepagel | Heparina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Hepamax s | Heparina | Heparina sodica | Nuparin | Sobrius</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Calciparin | Heparin | Heparin sodium rovi | Heparin wzf | Vasparin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Calciparina choay | Heparina leo | Heparina sodica chiesi | Heparina sodica pan quim | Heparina sodica rovi</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Heparin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Hepaflex | Heparin | Heparin leo | Thromboliquine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Heparine Calcium | Heparine calcium dakota | Heparine calcium panpharma | Heparine roche | Heparine Sodium | Heparine Sodium Panpharma | Heparine sodium roche | Prontoprime</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Heparin | Heparin boots | Heparin ca | Heparin ebl | Heparin immuno | Heparin na | Heparin pain/byrne | Heparin weddel | Minihep | Minihep calcium | Pump-hep | Trav heparin | Uniparin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Heparin | Heparin bichsel | Heplok</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Heparin novo | Heparinized saline</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Heparin Belupo</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Hepagusan | Heparin | Heparin Sodium B Braun | Inviclot</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Heparin | Heparin na | Heplok | Minihep | Minihep calcium | Multiparin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Heparin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Caprin | Cath-flush | Celhep | Celparin | Declot | Hep | Hep lock | Hepaglan | Heparen | Heparin | Hethin f | Keparin | Lofh | Lomorin | Neporin | Reniparin | Rinhepa | Thinla | Thiparin h | Thromboparin | Troyhep | V-parin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Calciparina | Croneparina | Ecafast | Ecasolv | Emoklar | Eparical | Eparina | Eparina calcica merck generics | Eparina calcica ratiopharm | Eparina calcica sandoz | Eparina novo | Eparina roberts | Eparina squibb | Eparina vister | Eparinger | Eparinlider | Eparven | Epsoclar | Eudipar | Flusolv | Heparinum | Liquemin | Normoparin | Pharepa | Reoflus | Sosefluss | Trombolisin | Zepac</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Heparin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Caprocin | Deribadex | Hepacarin | Hepafilled | Hepaflush | Heparin calcium ajinomoto | Heparin lente novo | Heparin mochida | Heparin na | Heparin na lock | Heparin organon | Heparin pf novo | Heparin pfizer | Heparin sodium ajinomoto | Heparin sodium fujo | Heparin sodium fuso | Heparin sodium mitsubishi | Heparin sodium mochida | Heparin sodium n | Heparin sodium n ay | Heparin sodium sankyo | Novo Heparin | Novo heparin aventis | Panheprin | Pemiroc</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Beparine | Bruhep | Celparin | Hepa | Heparen | Heparin indar | Heparin sodium fresenius | Heparine | Heparinol | Heparovit h | Medihep | Racil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bm heparin sodium | Calciparin | Gcc heparin sodium | Hanlim heparin sodium | Heparin | Heparin na | Huons heparin sodium | Huparin | Jw heparin | Jw heparin sodium | K heparin | Pain | Pine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Heparin leo</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Heparine | Heparine medis | Pharepa</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Calcium heparin | Heparin Natrium | Heparin panpharma | Heparin sanofi | Heparin sodica b. braun | Heparin sodium panpharma | Heparina sodica b braun | Heparinum wzf | Nevparin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Calparine | Heparine | Liquemine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Calcium heparin | Heparin | Heparin Natrium | Heparinum wzf | Nevparin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Heparine sodique roche | Liquemine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dixaparine | Hep-tec | Heparina | Heparina gi pisa | Inhepar | Proparin | Rimbipar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Eprin | Heparin | Heparinol | Unihepa | Vaxcel heparin sodium</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Heparin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Calparine | Heparine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Hepaflex | Heparin | Heparin campus | Heparin leo | Heparin panpharma | Monoparin | Nycoheparin | Pump-hep</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Monoparin | Multiparin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Heparina Sodic | Heparina sodica | Paripharm | Sobrius</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Britton heparin na | Bruhep | Cenprahep | Dega Heparin sodium (bovine) | Hemastat | Heparin | Hepasino | Hepastal | Heprin | Kabihep | Nuparin | Sakarin 25000</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ecafast | Heparin | Pine inj. | Vaxcel heparin sodium</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Coaparin | Heparin | Heparinum | Heparinum wzf</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Hep lock | Heparin | Heparin lock flush</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Heparina choay | Heparina sodica b braun | Heparina sodica rovi | Heparina zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actparin | Heparina leo | Heparina sodica fada pharma | Heparina sodica fusa | Heparina sodica prosalud | Rhoneparina sodica | Sobrius</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Heparin Leo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Heparin belmed</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Heparin sandoz | Heparin sodium braun</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Hikma heparin | Multiparin | Vaxcel heparin sodium</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Heparin Fermenta | Heparin leo</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Heparin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Heparin gilvasan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Heparin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hepamax s | Heparin | Heparin dbl | Nuparin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Cutheparine | Heparine | Heparine choay | Heparine medis</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Biemparin | Calciparine | Heparine Sodium | Heparinum | Heparx | Hexarin | Koparin | Liquemine | Poliparin | Seloparin | Vasparin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Agglutex | Cutheparine | Hepac | Hepac lock flush | Heparin | Heparin sodium fresenius | Hesharin | Pine | Sodium heparin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Gizende | Heparin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Hepanir</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Heparina | Heparina calcica | Heparina northia | Heparina sodica | Rhoneparina sodica | Riveparin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Heparina | Heparina sodica</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Henalip | Wellparin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Calciparine | Heparin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Heparin sodium fresenius</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Heparin | Heparin sodium fresenius</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22315269">
<a name="22315269"></a>Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e44S-e88S. doi: 10.1378/chest.11-2292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315269/pubmed" id="22315269" target="_blank">22315269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939938">
<a name="29939938"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy. <i>Obstet Gynecol</i>. 2018;132(1):e1-e17. doi: 10.1097/AOG.0000000000002706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/29939938/pubmed" id="29939938" target="_blank">29939938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25249585">
<a name="25249585"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2014;130(25):e433-e444]. <i>Circulation</i>. 2014;130(25):e344-e426. doi: 10.1161/CIR.0000000000000134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/25249585/pubmed" id="25249585" target="_blank">25249585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8134203">
<a name="8134203"></a>Andrew M, Marzinotto V, Massicotte P, et al, “Heparin Therapy in Pediatric Patients: A Prospective Cohort Study,” <i>Pediatr Research</i>, 1994, 35(1):78-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/8134203/pubmed" id="8134203" target="_blank">8134203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16537665">
<a name="16537665"></a>Antman EM, Morrow DA, McCabe CH, et al; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. <i>N Engl J Med</i>. 2006;354(14):1477-1488. doi: 10.1056/NEJMoa060898.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/16537665/pubmed" id="16537665" target="_blank">16537665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28416511">
<a name="28416511"></a>Arepally GM. Heparin-induced thrombocytopenia. <i>Blood</i>. 2017;129(21):2864-2872. doi:10.1182/blood-2016-11-709873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/28416511/pubmed" id="28416511" target="_blank">28416511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20059332">
<a name="20059332"></a>Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. <i>Annu Rev Med</i>. 2010;61:77-90. doi:10.1146/annurev.med.042808.171814<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/20059332/pubmed" id="20059332" target="_blank">20059332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33267665">
<a name="33267665"></a>Arepally GM, Padmanabhan A. Heparin-induced thrombocytopenia: a focus on thrombosis. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41(1):141-152. doi:10.1161/ATVBAHA.120.315445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/33267665/pubmed" id="33267665" target="_blank">33267665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27441664">
<a name="27441664"></a>Balestrino D, Quintana M, Charbonnel N, Forestier C, Lartigue C, Souweine B. Compatibility of injectable anticoagulant agents in ethanol; in vitro antibiofilm activity and impact on polyurethane catheters of enoxaparin 400 U/mL in 40% v/v ethanol. <i>PLoS One</i>. 2016;11(7):e0159475. doi: 10.1371/journal.pone.0159475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/27441664/pubmed" id="27441664" target="_blank">27441664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8141217">
<a name="8141217"></a>Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. <i>Am J Obstet Gynecol</i>. 1994;170(3):862-869. doi:10.1016/s0002-9378(94)70299-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/8141217/pubmed" id="8141217" target="_blank">8141217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18586569">
<a name="18586569"></a>Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton K. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. <i>Surg Obes Relat Dis</i>. 2008;4(6):748-753. doi: 10.1016/j.soard.2008.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/18586569/pubmed" id="18586569" target="_blank">18586569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315276">
<a name="22315276"></a>Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest.</i> 2012;141(2)(suppl):e691S-e736S. doi:10.1378/chest.11-2300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315276/pubmed" id="22315276" target="_blank">22315276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482767">
<a name="30482767"></a>Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. <i>Blood Adv</i>. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/30482767/pubmed" id="30482767" target="_blank">30482767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11176764">
<a name="11176764"></a>Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. <i>Arch Intern Med</i>. 2001;161(3):385-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/11176764/pubmed" id="11176764" target="_blank">11176764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bauer.2021">
<a name="Bauer.2021"></a>Bauer KA. Risk and prevention of venous thromboembolism in adults with cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bauer.2022">
<a name="Bauer.2022"></a>Bauer KA. Use of anticoagulants during pregnancy and postpartum. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955244">
<a name="19955244"></a>Bauer SR, Ou NN, Dreesman BJ, et al. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study. <i>Mayo Clin Proc</i>. 2009;84(12):1073-1078. doi: 10.4065/mcp.2009.0220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/19955244/pubmed" id="19955244" target="_blank">19955244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7053298">
<a name="7053298"></a>Bjornsson T, Wolfram B, Kitchell B. Heparin kinetics determined by three assay methods. <i>Clin Pharmacol Ther</i>. 1982;31(1):104–113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/7053298/pubmed" id="7053298" target="_blank">7053298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24296841">
<a name="24296841"></a>Bookstaver PB, Rokas KE, Norris LB, Edwards JM, Sherertz RJ. Stability and compatibility of antimicrobial lock solutions. <i>Am J Health Syst Pharm.</i> 2013;70(24):2185-2198. doi: 10.2146/ajhp120119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24296841/pubmed" id="24296841" target="_blank">24296841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193593">
<a name="19193593"></a>Bookstaver PB, Williamson JC, Tucker BK, Raad II, Sherertz RJ. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. <i>Ann Pharmacother.</i> 2009;43(2):210-219. doi: 10.1345/aph.1L145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/19193593/pubmed" id="19193593" target="_blank">19193593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14566272">
<a name="14566272"></a>Bottio T, Pittarello G, Bonato R, Fagiolo U, Gerosa G. Life-threatening anaphylactic shock caused by porcine heparin intravenous infusion during mitral valve repair. <i>J Thorac Cardiovasc Surg</i>. 2003;126(4):1194-1195. doi:10.1016/s0022-5223(03)00813-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/14566272/pubmed" id="14566272" target="_blank">14566272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27222450">
<a name="27222450"></a>Bradford NK, Edwards RM, Chan RJ. Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children: A systematic review. <i>Int J Nurs Stud</i>. 2016;59:51-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/27222450/pubmed" id="27222450" target="_blank">27222450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Braun.2019">
<a name="Braun.2019"></a>Braun JD. Embolism to the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17576891">
<a name="17576891"></a>Bruen KJ, Ballard JR, Morris SE, Cochran A, Edelman LS, Saffle JR. Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy. <i>Arch Surg</i>. 2007;142(6):546-551. doi:10.1001/archsurg.142.6.546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/17576891/pubmed" id="17576891" target="_blank">17576891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31433922">
<a name="31433922"></a>Burch HB. Drug effects on the thyroid. <i>N Engl J Med</i>. 2019;381(8):749-761. doi: 10.1056/NEJMra1901214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/31433922/pubmed" id="31433922" target="_blank">31433922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6878109">
<a name="6878109"></a>Burke BJ, Scott GL, Smith PJ, Wakerley GR. Heparin-associated priapism. <i>Postgrad Med J</i>. 1983;59(691):332-333. doi:10.1136/pgmj.59.691.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/6878109/pubmed" id="6878109" target="_blank">6878109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3545674">
<a name="3545674"></a>Butt W, Shann F, McDonnell G, Hudson I. Effect of heparin concentration and infusion rate on the patency of arterial catheters. <i>Crit Care Med</i>. 1987;15(3):230-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/3545674/pubmed" id="3545674" target="_blank">3545674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17000242">
<a name="17000242"></a>Casele H, Haney EI, James A, Rosene-Montella K, Carson M. Bone density changes in women who receive thromboprophylaxis in pregnancy. <i>Am J Obstet Gynecol</i>. 2006;195(4):1109-1113. doi:10.1016/j.ajog.2006.06.080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/17000242/pubmed" id="17000242" target="_blank">17000242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cloherty.2017">
<a name="Cloherty.2017"></a>Cloherty JP, Eichenwald EC, Martin CR, eds. <i>Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9250846">
<a name="9250846"></a>Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. <i>N Engl J Med</i>. 1997;337(7):447-452. doi: 10.1056/NEJM199708143370702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/9250846/pubmed" id="9250846" target="_blank">9250846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24794887">
<a name="24794887"></a>Conway MA, McCollom C, Bannon C. Central venous catheter flushing recommendations: a systematic evidence-based practice review. <i>J Pediatr Oncol Nurs</i>. 2014;31(4):185-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24794887/pubmed" id="24794887" target="_blank">24794887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27983747">
<a name="27983747"></a>Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. <i>Pharmacotherapy</i>. 2017;37(2):236-248. doi:10.1002/phar.1884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/27983747/pubmed" id="27983747" target="_blank">27983747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corkin.2015">
<a name="Corkin.2015"></a>Corkin MR, ed. <i>Pediatric Nutrition Support Core Curriculum</i>. 2nd edition. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1789820">
<a name="1789820"></a>Cruickshank MK, Levine MN, Hirsh J, et al, “A Standard Heparin Nomogram for the Management of Heparin Therapy,” <i>Arch Intern Med</i>, 1991, 151(2):333-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/1789820/pubmed" id="1789820" target="_blank">1789820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482768">
<a name="30482768"></a>Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Adv</i>. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/30482768/pubmed" id="30482768" target="_blank">30482768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cutlip.2020.1">
<a name="Cutlip.2020.1"></a>Cutlip D, Levin T. Antithrombotic therapy for elective percutaneous coronary intervention: general use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 6, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cutlip.2020.2">
<a name="Cutlip.2020.2"></a>Cutlip D, Lincoff AM. Anticoagulant therapy in non-ST elevation acute coronary syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17381384">
<a name="17381384"></a>Dager WE, Dougherty JA, Nguyen PH, et al. Heparin-Induced Thrombocytopenia: Treatment Options and Special Considerations. <i>Pharmacotherapy</i>. 2007;27(4):564-587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/17381384/pubmed" id="17381384" target="_blank">17381384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dager.2018">
<a name="Dager.2018"></a>Dager WE, Gulseth MP, Nutescu EA, eds. <i>Anticoagulation Therapy: A Clinical Practice Guide.</i> 2nd ed. American Society of Health-System Pharmacists; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20727512">
<a name="20727512"></a>Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. <i>Adv Chronic Kidney Dis</i>. 2010;17(5):420-427. doi:10.1053/j.ackd.2010.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/20727512/pubmed" id="20727512" target="_blank">20727512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25951901">
<a name="25951901"></a>Dager WE, Tsu LV, Pon TK. Considerations for Systemic Anticoagulation in ESRD. <i>Semin Dial</i>. 2015;28(4):354-362. doi:10.1111/sdi.12376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/25951901/pubmed" id="25951901" target="_blank">25951901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8178860">
<a name="8178860"></a>Dahlman TC, Sjöberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. <i>Am J Obstet Gynecol</i>. 1994;170(5 Pt 1):1315-1320. doi:10.1016/s0002-9378(94)70149-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/8178860/pubmed" id="8178860" target="_blank">8178860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Davenport.2020">
<a name="Davenport.2020"></a>Davenport A. Anticoagulation for continuous renal replacement therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. August 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care.</i> 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-473122">
<a name="473122"></a>Dawes J, Papper DS. Catabolism of low-dose heparin in man. <i>Thromb Res</i>. 1979;14(6):845-860.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/473122/pubmed" id="473122" target="_blank">473122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3917812">
<a name="3917812"></a>Decousus HA, Croze M, Levi FA, et al, “Circadian Changes in Anticoagulant Effect of Heparin Infused at a Constant Rate,” <i>Br Med J (Clin Res Ed)</i>, 1985, 290(6465):341-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/3917812/pubmed" id="3917812" target="_blank">3917812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7139119">
<a name="7139119"></a>de Swart C, Nijmeyer B, Roelofs J, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. <i>Blood</i>. 1982;60(6):1251–1258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/7139119/pubmed" id="7139119" target="_blank">7139119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8815571">
<a name="8815571"></a>Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. <i>Thromb Haemost</i>. 1996;75(2):254-257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/8815571/pubmed" id="8815571" target="_blank">8815571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.2019.1">
<a name="Pai.2019.1"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2019a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.2019.2">
<a name="Pai.2019.2"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.2020">
<a name="Pai.2020"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.<a href="http://www.uptodate.com" target="_blank"> http://www.uptodate.com</a>. Accessed December 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315266">
<a name="22315266"></a>Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;141(4):1129]. <i>Chest</i>. 2012;141(2 suppl):e326S-e350S. doi: 10.1378/chest.11-2298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315266/pubmed" id="22315266" target="_blank">22315266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6993082">
<a name="6993082"></a>Estes JW. Clinical pharmacokinetics of heparin. <i>Clin Pharmacokinet</i>. 1980;5(3):204-220. doi:10.2165/00003088-198005030-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/6993082/pubmed" id="6993082" target="_blank">6993082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315265">
<a name="22315265"></a>Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e278S-e325S. doi: 10.1378/chest.11-2404<b>.</b>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315265/pubmed" id="22315265" target="_blank">22315265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27919873">
<a name="27919873"></a>Faust AC, Kanyer D, Wittkowsky AK. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. <i>Am J Health Syst Pharm</i>. 2016;73(24):2037-2041. doi:10.2146/ajhp150596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/27919873/pubmed" id="27919873" target="_blank">27919873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15238590">
<a name="15238590"></a>Ferguson JJ, Califf RM, Antman EM, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. <i>JAMA</i>. 2004;292(1):45-54. doi: 10.1001/jama.292.1.45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/15238590/pubmed" id="15238590" target="_blank">15238590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8018004">
<a name="8018004"></a>Flaker GC, Bartolozzi J, Davis V, et al, “Use of a Standardized Heparin Nomogram to Achieve Therapeutic Anticoagulation after Thrombolytic Therapy in Myocardial Infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction,” <i>Arch Intern Med</i>, 1994, 154(13):1492-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/8018004/pubmed" id="8018004" target="_blank">8018004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4607271">
<a name="4607271"></a>Freed MD, Keane JF, and Rosenthal A, “The Use of Heparinization to Prevent Arterial Thrombosis After Percutaneous Cardiac Catheterization in Children,” <i>Circulation</i>, 1974, 50(3):565-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/4607271/pubmed" id="4607271" target="_blank">4607271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26895998">
<a name="26895998"></a>Gajic-Veljanoski O, Phua CW, Shah PS, Cheung AM. Effects of long-term low-molecular-weight heparin on fractures and bone density in non-pregnant adults: a systematic review with meta-analysis. <i>J Gen Intern Med</i>. 2016;31(8):947-957. doi:10.1007/s11606-016-3603-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/26895998/pubmed" id="26895998" target="_blank">26895998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315264">
<a name="22315264"></a>Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published corrections appear in <i>Chest</i>. 2012;141(5):1369; <i>Chest</i>. 2013;144(2):721]. <i>Chest.</i> 2012;141(2 suppl):e24S-e43S. doi: 10.1378/chest.11-2291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315264/pubmed" id="22315264" target="_blank">22315264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27840333">
<a name="27840333"></a>Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Circulation</i>. 2017;135(12):e791-e792]. <i>Circulation</i>. 2017;135(12):e726-e779. doi: 10.1161/CIR.0000000000000471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/27840333/pubmed" id="27840333" target="_blank">27840333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24404457">
<a name="24404457"></a>Gerlach AT, Folino J, Morris BN, Murphy CV, Stawicki SP, Cook CH. Comparison of heparin dosing based on actual body weight in non-obese, obese and morbidly obese critically ill patients. <i>Int J Crit Illn Inj Sci</i>. 2013;3(3):195-199. doi:10.4103/2229-5151.119200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24404457/pubmed" id="24404457" target="_blank">24404457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24226806">
<a name="24226806"></a>Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(24):2622-2703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24226806/pubmed" id="24226806" target="_blank">24226806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25950290">
<a name="25950290"></a>Gonzaga T, Jenabzadeh K, Anderson CP, Mohr WJ, Endorf FW, Ahrenholz DH. Use of intra-arterial thrombolytic therapy for acute treatment of frostbite in 62 patients with review of thrombolytic therapy in frostbite. <i>J Burn Care Res</i>. 2016;37(4):e323-e334. doi:10.1097/BCR.0000000000000245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/25950290/pubmed" id="25950290" target="_blank">25950290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315263">
<a name="22315263"></a>Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;141(5):1369]. <i>Chest</i>. 2012;141(2 suppl):e227S-e277S. doi: 10.1378/chest.11-2297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315263/pubmed" id="22315263" target="_blank">22315263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published corrections appear in <i>Chest</i>. 2012;141(4):1129; <i>Chest</i>. 2012;142(6):1698]. <i>Chest.</i> 2012;141(2 suppl):7S-47S. doi: 10.1378/chest.1412S3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15646699">
<a name="15646699"></a>Hansen LB, Vondracek SF. Prevention and treatment of nonpostmenopausal osteoporosis. <i>Am J Health Syst Pharm</i>. 2004;61(24):2637-2654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/15646699/pubmed" id="15646699" target="_blank">15646699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Heparin sodium in 0.45% sodium chloride [prescribing information]. Lake Forest, IL: Hospira Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Heparin sodium in 0.9% sodium chloride [prescribing information]. New York, NY: Pfizer Labs; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>Heparin sodium in dextrose injection [prescribing information]. Lake Forest, IL: Hospira Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Heparin sodium in sodium chloride 2 units/mL [prescribing information]. Lake Forest, IL: Hospira Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fesenius.1">
<a name="Fesenius.1"></a>Heparin sodium injection (single- and multi-dose vials) [prescribing information]. Lake Zurich, IL: Fesenius Kabi; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fesenius.2">
<a name="Fesenius.2"></a>Heparin sodium injection (single- and multi-dose vials) [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Heparin sodium injection [prescribing information]. Rockford, IL: Mylan; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Medefil.1">
<a name="Medefil.1"></a>Heparin Sodium (Porcine) Lock Flush [prescribing information]. Glendale Heights, IL: Medefil Inc; December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28552474">
<a name="28552474"></a>Hepponstall M, Chan A, Monagle P. Anticoagulation therapy in neonates, children and adolescents. <i>Blood Cells Mol Dis</i>. 2017;67:41-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/28552474/pubmed" id="28552474" target="_blank">28552474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31899512">
<a name="31899512"></a>Hickey S, Whitson A, Jones L, et al. Guidelines for thrombolytic therapy for frostbite. <i>J Burn Care Res</i>. 2020;41(1):176-183. doi:10.1093/jbcr/irz148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/31899512/pubmed" id="31899512" target="_blank">31899512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11413093">
<a name="11413093"></a>Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2001 Jun;103(24):2994-3018. doi:10.1161/01.cir.103.24.2994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/11413093/pubmed" id="11413093" target="_blank">11413093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8124829">
<a name="8124829"></a>Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. American Heart Association. <i>Circulation</i>. 1994;89(3):1449-1468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/8124829/pubmed" id="8124829" target="_blank">8124829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7555181">
<a name="7555181"></a>Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. <i>Chest</i>. 1995;108(4)(suppl):258S-275S. doi:10.1378/chest.108.4_supplement.258s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/7555181/pubmed" id="7555181" target="_blank">7555181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315259">
<a name="22315259"></a>Holbrook A, Schulman S, Witt, DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e152S-e184S. doi: 10.1378/chest.11-2295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315259/pubmed" id="22315259" target="_blank">22315259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28511582">
<a name="28511582"></a>Hosch LM, Breedlove EY, Scono LE, Knoderer CA. Evaluation of an unfractionated heparin pharmacy dosing protocol for the treatment of venous thromboembolism in nonobese, obese, and severely obese patients. <i>Ann Pharmacother</i>. 2017;51(9):768-773. doi:10.1177/1060028017709819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/28511582/pubmed" id="28511582" target="_blank">28511582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hull.2022.1">
<a name="Hull.2022.1"></a>Hull RD, Garcia DA. Heparin and LMW heparin: dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hull.2022.2">
<a name="Hull.2022.2"></a>Hull RD, Lip GYH. Venous thromboembolism: Anticoagulation after initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1497392">
<a name="1497392"></a>Hull RD, Raskob GE, Rosenbloom D, et al, “Optimal Therapeutic Level of Heparin Therapy in Patients with Venous Thromboembolism,” <i>Arch Intern Med</i>, 1992, 152(8):1589-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/1497392/pubmed" id="1497392" target="_blank">1497392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25687362">
<a name="25687362"></a>Ibrahim AE, Goverman J, Sarhane KA, Donofrio J, Walker TG, Fagan SP. The emerging role of tissue plasminogen activator in the management of severe frostbite. <i>J Burn Care Res</i>. 2015;36(2):e62-e66. doi:10.1097/BCR.0000000000000135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/25687362/pubmed" id="25687362" target="_blank">25687362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2011">
<a name="ISMP.2011"></a>Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, “Standard Concentrations of Neonatal Drug Infusions,” 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21422387">
<a name="21422387"></a>Jaff MR, McMurtry MS, Archer SL, et al, “Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,” <i>Circulation</i>, 2011, 123(16):1788-830.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/21422387/pubmed" id="21422387" target="_blank">21422387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267. doi: 10.1161/CIR.0000000000000041.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019. pii: S1547-5271(19)30037-2. doi: 10.1016/j.hrthm.2019.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21965579">
<a name="21965579"></a>Johnson AR, Jensen HL, Peltier G, DelaCruz E. Efficacy of intravenous tissue plasminogen activator in frostbite patients and presentation of a treatment protocol for frostbite patients. <i>Foot Ankle Spec</i>. 2011;4(6):344-348. doi:10.1177/1938640011422596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/21965579/pubmed" id="21965579" target="_blank">21965579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315261">
<a name="22315261"></a>Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e195S-e226S. doi: 10.1378/chest.11-2296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315261/pubmed" id="22315261" target="_blank">22315261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1505142">
<a name="1505142"></a>Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. <i>Clin Pharmacokinet</i>. 1992;22(5):359-374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/1505142/pubmed" id="1505142" target="_blank">1505142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26161162">
<a name="26161162"></a>Kapetanakis S, Nastoulis E, Demesticha T, Demetriou T. The effect of low molecular weight heparins on fracture healing. <i>Open Orthop J</i>. 2015;9:226-236. doi:10.2174/1874325001509010226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/26161162/pubmed" id="26161162" target="_blank">26161162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24801362">
<a name="24801362"></a>Karlaftis V, Sritharan G, Attard C, Corral J, Monagle P, Ignjatovic V. Beta (β)-antithrombin activity in children and adults: implications for heparin therapy in infants and children. <i>J Thromb Haemost</i>. 2014;12(7):1141-1144. doi:10.1111/jth.12597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24801362/pubmed" id="24801362" target="_blank">24801362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381464">
<a name="31381464"></a>Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2020;38(5):496-520. doi:10.1200/JCO.19.01461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/31381464/pubmed" id="31381464" target="_blank">31381464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kincaid.2014">
<a name="Kincaid.2014"></a>Kincaid EH, Hammon JW. Cardiopulmonary Bypass. In: Yuh DD, Vricella LA, Yang SC, Doty JR. eds. <i>Johns Hopkins Textbook of Cardiothoracic Surgery, Second Edition. </i>New York, NY: McGraw-Hill; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaasch.2019a">
<a name="Gaasch.2019a"></a>Konkle BA, Nkomo VT. Antithrombotic therapy for mechanical heart valves. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kovalik.2020">
<a name="Kovalik.2020"></a>Kovalik EC, Davenport A. Anticoagulation for the hemodialysis procedure. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20868290">
<a name="20868290"></a>Krishnaswamy A, Lincoff AM, Cannon CP. Bleeding complications of unfractionated heparin. <i>Expert Opin Drug Saf</i>. 2011;10(1):77-84.doi: 10.1517/14740338.2011.521150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/20868290/pubmed" id="20868290" target="_blank">20868290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1678033">
<a name="1678033"></a>Kroon C, de Boer A, Kroon JM, Schoemaker HC, van den Meer FJ, Cohen AF. Influence of skinfold thickness on heparin absorption. <i>Lancet</i>. 1991;337(8747):945-946. doi:10.1016/0140-6736(91)91573-d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/1678033/pubmed" id="1678033" target="_blank">1678033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16427905">
<a name="16427905"></a>Kulik A, Rubens FD, Wells PS, et al. Early postoperative anticoagulation after mechanical valve replacement: a systematic review. <i>Ann Thorac Surg.</i> 2006;81(2):770-781. doi: 10.1016/j.athoracsur.2005.07.023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/16427905/pubmed" id="16427905" target="_blank">16427905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17040550">
<a name="17040550"></a>Lee OK, Johnston L. A systematic review for effective management of central venous catheters and catheter sites in acute care paediatric patients. <i>Worldviews Evid Based Nurs</i>. 2005;2(1):4-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/17040550/pubmed" id="17040550" target="_blank">17040550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32885997">
<a name="32885997"></a>Levito MN, Coons JC, Verrico MM, et al. A systemwide approach for navigating the dilemma of oral factor Xa inhibitor interference with unfractionated heparin anti-factor Xa concentrations. <i>Ann Pharmacother</i>. Published online September 4, 2020. doi:10.1177/1060028020956271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/32885997/pubmed" id="32885997" target="_blank">32885997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lincoff.2020">
<a name="Lincoff.2020"></a>Lincoff AM, Cutlip D. Acute ST-elevation myocardial infarction: Management of anticoagulation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315270">
<a name="22315270"></a>Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e495S-e530S. doi:10.1378/chest.11-2303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315270/pubmed" id="22315270" target="_blank">22315270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lip.2022">
<a name="Lip.2022"></a>Lip GYH, Hull RD. Venous thromboembolism: Initiation of anticoagulation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16634744">
<a name="16634744"></a>Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. <i>J Thromb Haemost</i>. 2006;4(4):759-65. doi:10.1111/j.1538-7836.2006.01787.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/16634744/pubmed" id="16634744" target="_blank">16634744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Malhotra.1">
<a name="Malhotra.1"></a>Malhotra A. Venous thromboembolism in pregnancy and postpartum: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20235296">
<a name="20235296"></a>Mathews EZ. A fatal case of heparin-induced thrombocytopenia and thrombosis. <i>J Hosp Med</i>. 2010;5(3):E14-5. doi:10.1002/jhm.512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/20235296/pubmed" id="20235296" target="_blank">20235296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7254945">
<a name="7254945"></a>McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. <i>Pediatr Res</i>. 1981;15(7):1015-1018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/7254945/pubmed" id="7254945" target="_blank">7254945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31326282">
<a name="31326282"></a>McIntosh SE, Freer L, Grissom CK, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of frostbite: 2019 update. <i>Wilderness Environ Med</i>. 2019;30(4S):S19-S32. doi:10.1016/j.wem.2019.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/31326282/pubmed" id="31326282" target="_blank">31326282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18657648">
<a name="18657648"></a>Melloni C, Alexander KP, Chen AY, et al. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. <i>Am Heart J</i>. 2008;156(2):209-215. doi:10.1016/j.ahj.2008.03.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/18657648/pubmed" id="18657648" target="_blank">18657648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published corrections appear in <i>Clin Infect Dis.</i> 2010;50(7):1079; <i>Clin Infect Dis.</i> 2010;50(3):457]. <i>Clin Infect Dis. 2</i>009;49(1):1-45. doi: 10.1086/599376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315277">
<a name="22315277"></a>Monagle P, Chan A, Goldenberg NA, et al, "Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition)," <i>Chest</i>, 2012, 141(2 Suppl):e737-801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315277/pubmed" id="22315277" target="_blank">22315277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32904403">
<a name="32904403"></a>Moreno-Duarte I, Ghadimi K. Heparin induced thrombocytopenia for the perioperative and critical care clinician. <i>Curr Anesthesiol Rep</i>. 2020;10(4):501-511. doi:10.1007/s40140-020-00405-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/32904403/pubmed" id="32904403" target="_blank">32904403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22177816">
<a name="22177816"></a>Morimoto Y, Niwa H, Minematsu K. Risk factors affecting hemorrhage after tooth extraction in patients undergoing continuous infusion with unfractionated heparin. <i>J Oral Maxillofac Surg</i>. 2012;70(3):521-526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22177816/pubmed" id="22177816" target="_blank">22177816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25899949">
<a name="25899949"></a>Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. <i>Reg Anesth Pain Med</i>. 2015;40(3):182-212. doi:10.1097/AAP.0000000000000223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/25899949/pubmed" id="25899949" target="_blank">25899949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.2019">
<a name="Nemecek.2019"></a>Nemecek BD, Hammond DA, eds. <i>Demystifying Drug Dosing in Renal Dysfunction</i>. American Society of Health-System Pharmacists; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19221154">
<a name="19221154"></a>Newall F, Johnston L, Ignjatovic V, et al, "Unfractionated Heparin Therapy in Infants and Children," <i>Pediatrics</i>, 2009, 123(3):e510-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/19221154/pubmed" id="19221154" target="_blank">19221154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nkomo.2023">
<a name="Nkomo.2023"></a>Nkomo VT, Konkle BA. Anticoagulation for prosthetic heart valves: management of bleeding and invasive procedures. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27606554">
<a name="27606554"></a>Nygaard RM, Lacey AM, Lemere A, et al. Time matters in severe frostbite: assessment of limb/digit salvage on the individual patient level. <i>J Burn Care Res</i>. 2017;38(1):53-59. doi:10.1097/BCR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/27606554/pubmed" id="27606554" target="_blank">27606554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23256914">
<a name="23256914"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol.</i> 2013;61(4):e78-e140. doi: 10.1016/j.jacc.2012.11.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/23256914/pubmed" id="23256914" target="_blank">23256914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13940090">
<a name="13940090"></a>Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin: An experimental study on dogs and humans. <i>Acta Med Scand</i>. 1963;173:619–630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/13940090/pubmed" id="13940090" target="_blank">13940090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33007077">
<a name="33007077"></a>Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Adv</i>. 2020;4(19):4693-4738. doi:10.1182/bloodadvances.2020001830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/33007077/pubmed" id="33007077" target="_blank">33007077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33861298">
<a name="33861298"></a>Osataphan S, Patell R, Chiasakul T, Khorana AA, Zwicker JI. Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. <i>Blood Adv.</i> 2021;5(8):2055-2062. doi:10.1182/bloodadvances.2020004118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/33861298/pubmed" id="33861298" target="_blank">33861298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32341921">
<a name="32341921"></a>Paine RE, Turner EN, Kloda D, Falank C, Chung B, Carter DW. Protocoled thrombolytic therapy for frostbite improves phalangeal salvage rates. <i>Burns Trauma</i>. 2020;8:tkaa008. doi:10.1093/burnst/tkaa008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/32341921/pubmed" id="32341921" target="_blank">32341921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25342997">
<a name="25342997"></a>Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. <i>Ther Adv Musculoskelet Dis</i>. 2014;6(5):185-202. doi:10.1177/1759720X14546350<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/25342997/pubmed" id="25342997" target="_blank">25342997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27624773">
<a name="27624773"></a>Pasquale LD, Ferneini EM. Heparin and Lovenox: What the Oral and Maxillofacial Surgeon Needs to Know. <i>Oral Maxillofac Surg Clin North Am</i>. 2016;28(4):507-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/27624773/pubmed" id="27624773" target="_blank">27624773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30071480">
<a name="30071480"></a>Patanwala AE, Seaman SM, Kopp BJ, Erstad BL. Heparin dosing for venous thromboembolism prophylaxis in obese hospitalized patients: an observational study. <i>Thromb Res</i>. 2018;169:152-156. doi:10.1016/j.thromres.2018.07.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/30071480/pubmed" id="30071480" target="_blank">30071480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8214998">
<a name="8214998"></a>Raschke RA, Reilly BM, Guidry JR, et al, “The Weight-Based Heparin Dosing Nomogram Compared With a “Standard Care” Nomogram: A Randomized Controlled Trial,” <i>Ann Intern Med</i>, 1993, 119(9):874-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/8214998/pubmed" id="8214998" target="_blank">8214998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20587743">
<a name="20587743"></a>Riney JN, Hollands JM, Smith JR, Deal EN. Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. <i>Ann Pharmacother</i>. 2010;44(7-8):1141-1151. doi:10.1345/aph.1P088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/20587743/pubmed" id="20587743" target="_blank">20587743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25736986">
<a name="25736986"></a>Samuel S, Iluonakhamhe EK, Adair E, et al. High dose subcutaneous unfractionated heparin for prevention of venous thromboembolism in overweight neurocritical care patients. <i>J Thromb Thrombolysis</i>. 2015;40(3):302-307. doi:10.1007/s11239-015-1202-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/25736986/pubmed" id="25736986" target="_blank">25736986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22863355">
<a name="22863355"></a>Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?<i> J Thromb Haemost.</i> 2012;10(10):2053-2060. doi: 10.1111/j.1538-7836.2012.04874.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22863355/pubmed" id="22863355" target="_blank">22863355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22560830">
<a name="22560830"></a>Shen JI, Winkelmayer WC. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. <i>Am J Kidney Dis.</i> 2012;60(3):473-486. doi:10.1053/j.ajkd.2012.03.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22560830/pubmed" id="22560830" target="_blank">22560830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26236941">
<a name="26236941"></a>Shin S, Harthan EF. Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review. <i>Blood Coagul Fibrinolysis</i>. 2015;26(6):655-660. doi:10.1097/MBC.0000000000000336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/26236941/pubmed" id="26236941" target="_blank">26236941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31623539">
<a name="31623539"></a>Shlensky JA, Thurber KM, O'Meara JG, et al. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping. <i>Vasc Med</i>. 2020;25(1):47-54. doi:10.1177/1358863X19875813<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/31623539/pubmed" id="31623539" target="_blank">31623539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31652944">
<a name="31652944"></a>Signorelli SS, Scuto S, Marino E, Giusti M, Xourafa A, Gaudio A. Anticoagulants and osteoporosis. <i>Int J Mol Sci</i>. 2019;20(21):5275. doi:10.3390/ijms20215275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/31652944/pubmed" id="31652944" target="_blank">31652944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20411994">
<a name="20411994"></a>Smythe MA, Nutescu EA, and Wittkowsky AK, "Changes in the USP Heparin Monograph and Implications for Clinicians," <i>Pharmacotherapy</i>, 2010, 30(5):428-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/20411994/pubmed" id="20411994" target="_blank">20411994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20805623">
<a name="20805623"></a>Steg PG, Jolly SS, Mehta SR, et al; FUTURA/OASIS-8 Trial Group. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. <i>JAMA</i>. 2010;304(12):1339-1349. doi: 10.1001/jama.2010.1320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/20805623/pubmed" id="20805623" target="_blank">20805623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24171490">
<a name="24171490"></a>Steg PG, van 't Hof A, Hamm CW, et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. <i>N Engl J Med</i>. 2013;369(23):2207-2217. doi: 10.1056/NEJMoa1311096.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24171490/pubmed" id="24171490" target="_blank">24171490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17124018">
<a name="17124018"></a>Stone GW, McLaurin BT, Cox DA, et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. <i>N Engl J Med</i>. 2006;355(21):2203-2216. doi: 10.1056/NEJMoa062437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/17124018/pubmed" id="17124018" target="_blank">17124018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26358792">
<a name="26358792"></a>Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-associated venous thromboembolic disease, version 1.2015. <i>J Natl Compr Canc Netw</i>. 2015;13(9):1079-1095. doi:10.6004/jnccn.2015.0133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/26358792/pubmed" id="26358792" target="_blank">26358792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15875438">
<a name="15875438"></a>Su HM, Voon WC, Chu CS, Lin TH, Lai WT, Sheu SH. Heparin-induced cardiac tamponade and life-threatening hyperkalema in a patient with chronic hemodialysis. <i>Kaohsiung J Med Sci</i>. 2005;21(3):128-233. doi:10.1016/s1607-551x(09)70289-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/15875438/pubmed" id="15875438" target="_blank">15875438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tapson.2019">
<a name="Tapson.2019"></a>Tapson VF, Weinberg AS. Thrombolytic (fibrinolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081526">
<a name="33081526"></a>Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16 Suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/33081526/pubmed" id="33081526" target="_blank">33081526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32164041">
<a name="32164041"></a>Tsujimoto H, Tsujimoto Y, Nakata Y, et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. <i>Cochrane Database Syst Rev.</i> Published online March 13, 2020. doi:10.1002/14651858.CD012467.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/32164041/pubmed" id="32164041" target="_blank">32164041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531940">
<a name="22531940"></a>Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. <i>Pharmacotherapy</i>. 2012;32(6):546-558. doi: 10.1002/j.1875-9114.2011.01049.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22531940/pubmed" id="22531940" target="_blank">22531940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23379279">
<a name="23379279"></a>Wada H, Thachil J, Di Nisio M, Mathew P, et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines [published online February 4, 2013]. <i>J Thromb Haemost. </i>doi: 10.1111/jth.12155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/23379279/pubmed" id="23379279" target="_blank">23379279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12847070">
<a name="12847070"></a>Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. <i>Circulation</i>. 2003;108(2):135-142. doi: 10.1161/01.CIR.0000081659.72985.A8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/12847070/pubmed" id="12847070" target="_blank">12847070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11320387">
<a name="11320387"></a>Warkentin TE and Kelton JG, “Temporal Aspects of Heparin-Induced Thrombocytopenia,” <i>N Engl J Med</i>, 2001, 344(17):1286-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/11320387/pubmed" id="11320387" target="_blank">11320387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315272">
<a name="22315272"></a>Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e576S-e600S. doi: 10.1378/chest.11-2305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315272/pubmed" id="22315272" target="_blank">22315272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29533476">
<a name="29533476"></a>Yamaji H, Murakami T, Hina K, et al. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. <i>J Cardiovasc Electrophysiol</i>. 2018;29(6):835-843. doi: 10.1111/jce.13483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/29533476/pubmed" id="29533476" target="_blank">29533476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32520445">
<a name="32520445"></a>Yang S, Niu Q, Gan L, Zhang X, Tu L, Zuo L. Effect of long-term use of unfractionated or low-molecular-weight heparin on bone mineral density in maintenance hemodialysis patients. <i>Hemodial Int</i>. 2020;24(3):374-382. doi:10.1111/hdi.12854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/32520445/pubmed" id="32520445" target="_blank">32520445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635828">
<a name="17635828"></a>Yevzlin AS, Sanchez RJ, Hiatt JG, et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. <i>Semin Dial.</i> 2007;20(4):351-354. doi: 10.1111/j.1525-139X.2007.00294.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/17635828/pubmed" id="17635828" target="_blank">17635828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315271">
<a name="22315271"></a>You JJ, Singer DE, Howard PA, et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e531S-e575S. doi: 10.1378/chest.11-2304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315271/pubmed" id="22315271" target="_blank">22315271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zafren.1">
<a name="Zafren.1"></a>Zafren K, Mechem CC. Frostbite: Emergency care and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10927736">
<a name="10927736"></a>Zidane M, Schram MT, Planken EW, Molendijk WH, Rosendaal FR, van der Meer FJ, Huisman MV. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. <i>Arch Intern Med</i>. 2000;160(15):2369-2373. doi:10.1001/archinte.160.15.2369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/10927736/pubmed" id="10927736" target="_blank">10927736</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13349 Version 626.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
